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BACKGROUND 
Immunogenetics 
Immunogenetics is a scientific discipline that uses immunological methods to study the inheritance 
of traits. Traditionally, immunogenetics has been concerned with moieties that elicit immune 
response, that is, with antigens (antigenic determinants). It has now broadened its scope to study 
also the genetic control of the individual's ability to respond to an antigen. The immunological 
methods used in immunogenetics are of two principal kinds, serological and histogenetical. In 
serological methods, antibodies are used to detect antigens, either in solution or on a cell surface. In 
histogenetical methods, immune cells (lymphocytes) are used to detect antigens on the surface of 
other cells. In modern immunogenetics research, the serological and histogenetical methods are 
combined with molecular methods in which the researcher isolates and works with the genes that 
code for the traits. This approach of going back and forth from classical to molecular methods has 
proved to be very successful and has led to the elucidation of several complex genetic systems.   
 
Granulomatous Lung Disease 
Granulomatous lung diseases, such as  sarcoidosis, hypersensitivity pneumonitis, Wegener's 
granulomatosis, and chronic beryllium disease, along with granulomatous diseases of known 
infectious etiologies, such as tuberculosis, are major causes of morbidity and mortality throughout 
the world. Clinical manifestations of these diseases are highly heterogeneous, and the determinants 
of disease susceptibility and clinical course (e.g., resolution vs. chronic, progressive fibrosis) are 
largely unknown. The underlying pathogenic mechanisms of these diseases also remain poorly 
understood. Within this context, these diseases have been approached using genomic and proteomic 
technologies to allow us to identify patterns of gene/protein expression that track with clinical 
disease or to identify new pathways involved in disease pathogenesis. The results from these initial 
studies highlight the potential for these "-omics" approaches to reveal novel insights into the 
pathogenesis of granulomatous lung disease and provide new tools to improve diagnosis, clinical 
classification, course prediction, and response to therapy. Realizing this potential will require 
collaboration among multidisciplinary groups with expertise in the respective technologies, 
bioinformatics, and clinical medicine for these complex diseases. 
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IMMUNOGENETICS OF TUBERCULOSIS 
 
EVALUATION OF A MULTI-ANTIGEN TEST BASED ON B-CELL EPITOPES PEPTIDES FOR 
THE SERODIAGNOSIS OF PULMONARY TUBERCULOSIS 
 
Abstract 
SETTING: Two sample panels: (i) twenty pulmonary tuberculosis (TBp) patients and ten healthy 
subjects (HS) from a country with low incidence of TB (Italy) and (ii) forty-seven TBp patients and 
26 HS from a country with high incidence of TB (Morocco). 
OBJECTIVE: To identify a combination of Mycobacterium tuberculosis (Mtb) peptides useful for 
the serodiagnosis of active TBp. 
METHODS: Fifty-seven B-cell epitopes peptides of Mtb were evaluated by immunoenzymatic 
assay and the data were analyzed using logistic regression analysis and Random Forest method. 
RESULTS: The best discriminating peptide between TBp patients and HS from the sample of the 
country with low incidence of TB has been the 23 amino acid peptide of the Rv3878 protein.  Thus, 
the sensitivity and specificity was 65 % and 100 %, respectively. In contrast, the same peptide 
showed 47% and 100% as sensitivity and specificity respectively in the country with high incidence 
of TB. In addition, the best peptides combination was a pool of nine peptides which showed a 
sensitivity of 70.2% and a specificity of 100% in the country with high incidence of TB. 
CONCLUSIONS: The 9-peptides pool can be useful in identifying patients with active TBp 
  
Keywords : Tuberculosis, peptides, serodiagnosis, B-cell epitope, ELISA 
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Introduction 
Tuberculosis (TB) remains a major public health problem in most developing countries. The 
global annual incidence of tuberculosis has been estimated at 8 to 10 million cases, with 
approximately 1.7 million deaths (1). The control of the disease depends largely on early detection 
and the treatment of active cases. 
At present, efforts at developing immunological tests are directed towards the identification 
of novel antigens that are associated with active disease. Thus the major objective of current 
immunological studies in TB is the identification of species-specific antigens and determination of 
the significance of corresponding immune responses. In this context, it is reasonable to hypothesize 
that proteins preferentially expressed by Mtb in models of intracellular growth and infection might 
be ideal targets for the design of new, highly sensitive  diagnostic tests of Mtb infection and, 
eventually, for vaccine design (2, 3). 
Serodiagnosis tests like enzyme linked immuno-sorbent assay (ELISA) are promising in 
view of their ease of performance and cost-effectiveness, many studies have been carried out by 
using quite complex antigens, such as whole bacteria, culture filtrates, bacterial extracts, and 
tuberculin or their purified protein derivatives (PPD) (4-6). However, a large variability in 
diagnostic accuracy has been reported, depending on the antigen employed and on the heterogeneity 
of the antibody response in TB patients(7). 
The use of biochemical purification methods and recombinant DNA techniques of natural 
and recombinant proteins to obtain mycobacterial antigens is a challenging task with high cost and 
low specificities of the assays based on these antigens (8, 9). Therefore, we used synthetic peptides 
to assess their antibody responses in tuberculosis patients.  Furthermore, the in silico approach 
based on screening of Mtb coding sequences from the proteins databases by using the prediction 
programs algorithms to identify B-cell epitopes is promising, since it reduce the cost of synthesizing 
peptides by reducing the number of peptides required for experimental evaluation for antibody 
reactivity (10, 11). 
In this study, we assessed the potential use of the in-silico selection approach of M. tuberculosis-
specific synthetic peptides in the serodiagnosis of active tuberculosis. 
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Materials and methods 
Study population 
To identify the immunological relevant peptides between the in-silico selected peptides, a first panel 
of sera from a country with low incidence of tuberculosis (Italy) were analysed. Specifically, 10 
sera from skin test negative (TST-negative) healthy subjects without any history of TB exposure 
and 20 sera from active TB patients enrolled at Division of Respiratory Medicine of the University 
of Rome “Tor Vergata”, at the “L. Spallanzani” Institute (Roma, Italy). The diagnosis of active TB 
was microbiologically confirmed by culture isolation of Mtb in all TB cases. Patient’s details are 
shown in Table 1.  
A second panel of sera from a country with high level of TB incidence has been used to evaluate the 
relevant peptide and the pool of peptides selected with the first study population. To this end, 47 
patients with pulmonary active tuberculosis from Morocco were evaluated (Table 1). All patients 
underwent to smear and culture examination for Mtb according to standard procedures. 
Specifically, 31 Smear and culture positive (S+C+) patients and 16 smear-negative, culture-positive 
(S-C+) TB patients were evaluated in the study (table 1). Further, sera from twenty-six skin test 
positive healthy voluntary donors were collected from the Blood transfusion Regional Center 
(CRTS) of Rabat, Morocco. 
All study subjects were found to be HIV negative. Sera from all patients were collected 
before anti-tuberculous treatment and were stored at -20°C until use. 
The B-cell epitopes selection  
Fifty-seven synthetic peptides containing potential B-cell epitopes were selected by in-silico 
strategy from 25 proteins of Mtb. Briefly, the sequence of Mtb proteins belonging to RD1 genomic 
region (12) and of proteins expressed during Mtb growth in human macrophage (2, 3), was obtained 
by the Swiss-Prot database (Table 2). Each single protein was screened for potential B-cell epitopes 
by using three computer algorithms of antigenicity: the Jameson-Wolf index, the Hopp-Woods 
method and the Parker index. These algorithms, available with Genrunner software [Hastings 
Software, Inc., Hastings, N.Y.] and Antheprot software (13-15), predict antigenic regions based on 
probability of surface exposure, local hydrophobicity, beta turns amino acid sequence, atomic 
flexibility and experimental HPLC retention times of synthetic peptides. Only protein regions 
identified as containing B-cell epitopes by at least two algoritms were selected. 
Finally, the sequence of each epitope was screened for homology search of all known protein 
sequences by BLAST (http://www.ebi.ac.uk/blast/) through the selection of peptides that are 
uniquely restricted to the Mtb-complex (homology lower than 80% compared to other bacteria). 
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 The sequence of all the selected peptides is reported on Table 2. 
Peptides 
The peptides were synthesized by Fmoc chemistry as free amino acid termini by ABI 
(http://www.abi.it/). All peptides were purified by reverse-phase chromatography (RPC). The purity 
of the purified peptides was higher than 90%. Sequence and purity were confirmed by mass 
spectrometry and analytical RPC. Lyophilized peptides were diluted in DMSO at stock 
concentrations of 10 mg/ml for each peptide and stored at – 80°C until use. 
Peptide-based ELISA 
Ninety-six wells high-binding capacity flat-bottom microplate (Greiner) was coated with 1 
µg per well of each peptide in a Phosphate Buffered saline (PBS) buffer (pH 7.4) and kept at 4°C 
overnight. Then the plate was washed with 0.05% (v/v) Tween-20 in PBS and blocked with 3 % of 
bovine serum albumin (BSA, Sigma) for 1 hour. Each sample was assayed at a 1:50 dilution (2 
hours, at room temperature). A horseradish peroxidase (HRP) conjugated anti-human IgG was used 
as the second antibody. The reaction was revealed using Ortho-Phenyl-Diamine (OPD)/H2O2 
(Sigma) and quantified using an ELISA reader at 450 nm after stopping the reaction with 0.5M 
H2S04. Blank wells were included as negative control in this assay. 
Statistical analysis 
Test results are presented as means ± standard deviation (SD) of the mean. ELISA tests were scored 
positive when individual readings were greater than two standards deviations above the optical 
density average of healthy subjects. Comparisons between different groups were made by Mann-
Whitney test. 
The best peptides discriminating between TB patients and controls sera were identified by using 
univariate logistic regression model using Statistical Package for Social Science™ (SPSS version 
15), the Random Forests Method [http://genesrf.bioinfo.cnio.es/] (16) and stepwise multivariate 
logistic regression model using SPSS program. 
The Receiver Operating Characteristic (ROC) curve was used to evaluate the performance of the 
ELISA tests with the two categories (TB patients and controls) ; the Area Under the Receiver 
Operating Characteristic curve (AUC) was used as a measure of diagnostic quality. The cut-off 
value used here is the one that leads to a ≥ 50% probability of being a case. 
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Results 
In order to identify peptides capable of being recognized by TB patients, a first panel of TB and 
control sera from a low incidence country for TB was tested. Figure 1 shows the IgG response 
against each one of the fifty-seven selected peptides containing potential B–cell epitope (Figure 1). 
The antibody responses against the peptides were variable (figure.1). Univariate logistic regression 
method showed that the best discrimination score value between TB and healthy controls was 
12.128 obtained with the peptide Pep51 of the Rv3878 protein (see for sequence table 2). With a 
2SD cut-off value, the sensitivity and specificity was 65 % and 100% respectively and the area-
under-the-ROC curve was 0.912 (Figure 2).   
When multivariate logistic regression method and random Forest method were used, the best 
peptides combination identified was: Pep5 (Rv0747), Pep11 (Rv1114), Pep14 (Rv1434), Pep26 
(Rv1979c), Pep42 (Rv3736), Pep48 (Rv3874 also known as CFP10), Pep51 (Rv3878), Pep55 
(Rv3883) and Pep57 (Rv3883).  
The peptides identified were then used in a second population from a country with high incidence 
of TB in order to evaluate their performances in the diagnosis of active TB.  
The results of the ELISA based on the peptide Pep51 alone among the forty-seven TB patients and 
the twenty-six healthy controls showed a sensitivity and specificity of 47% and 100% respectively 
with a cut-off value at 2SD of the controls and the area-under-the-ROC curve was 0.842 (Figure 3). 
However, the results among the same population but with the ELISA based on the selected 9-
peptides showed a higher value (0.938) of the area-under-the-ROC curve (P value=0.04) (Figure 4). 
Further, figure 5 shows the box plots of the antibody titer obtained with the second panel sera of TB 
and healthy controls. With a cut-off value at 2SD of the controls, the sensitivity and specificity was 
70.2 % and 100% respectively (Figure4).  
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Discussion 
The availability of mycobacterial genome sequences, the development of chemical synthesis 
techniques of peptides and the development of algorithms for the identification of immunodominant 
B-cell epitopes, might determine the rapid identification and testing of epitopes with diagnostic 
potential for active TB with the advantage of reducing the number of experimental evaluations for 
antibody reactivity. In fact, the use of ELISA test based on synthetic peptides would in principle 
circumvent the technical complexity and potential antigen variability associated with antigen 
purification. Further, synthetic peptides used as antigens have the added advantage of avoiding 
contamination with low-level impurities derived from cloning vectors required to produce 
recombinant proteins. Such impurities could decrease the specificity of the assay if they were cross-
reactive with M. tuberculosis antigens. Finally, using synthetic peptides as the diagnostic antigen 
permit the uniformity and standardization of antigen preparations (17). 
However, the main problem in setting immunodiagnostic systems is the identification of 
immunodominant antigen(s) specific of the active disease phase. In this context, previous studies (2, 
3), have shown that Mtb is capable of expressing differential transcription programs in response to 
different environments. In particular, Mtb can express different gene sets in synthetic media 
compared to macrophage cultures. For instance, RD1 proteins are expressed both in early and late 
phase cultures, are variably expressed in in vivo in murine models, but are expressed at very low 
level in macrophage cultures (2, 3, 18-20).  
With this background, we hypothesized that the Mtb proteins overexpressed in a model of Mtb 
infection in macrophage cultures could be the specific target of a strong immune response in active 
TB subjects. Thus, we combined the use of relevant Mtb antigen in a model of Mtb infection with in 
silico approach to identify B-cell epitopes to evaluate their potential use in TB serodiagnosis. 
We were able to identify a peptide belonging to the Mtb protein Rv3878, as the best discriminating 
peptide between TB patients and healthy controls among a population of low exposure level of TB. 
Rv3878 is one the proteins encoded by RD1, a region present in Mtb and virulent M. bovis genomes 
but missing from the DNA of all substrains of M. bovis Bacillus Calmette-Guerin (BCG) (12).  
Although our findings are not in agreement with previous observation by Brusasca et al (21) who 
reported that only 3–7% of human TB patients responded to RD1 region proteins, including 
Rv3878, it is well known that all RD1 antigens elicited a high antibody response in guinea-pigs 
infected with Mtb (21). Further, in a recent study (22), it has been shown that the Rv3878 protein 
elicited strong humoral immune response in TB patients in Indian population, supporting the notion 
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that the antibody response to a specific antigen often depends on the geographical location and 
ethnic background of the population being studied (23).  
Several studies indicate that combinations of mycobacterial antigens are likely to have better 
diagnostic value (24, 25). Using both multivariate logistic regression analysis and  random Forest 
method, we were able to identify a pool of 9-peptides beloning to the proteins  Rv0747, Rv1114, 
Rv1434, Rv1979c, Rv3874, Rv3736, Rv3878 and Rv3883 as the best discriminating peptides 
combination between TB patients and healthy controls.  
Recent reports indicate that the antigen Rv3874 is frequently recognized by antibodies in patients 
with TB, from regions where TB is not endemic (21) and from regions where TB is endemic (26). 
Further, Rv3883c or Mycosin-1 is an extra-cellular protein that is membrane- and cell wall-
associated, and is shed into the culture supernatant. The protein is expressed after infection of 
Macrophages (27), but Rv3883C is not expressed in the attenuated M. bovis  strain BCG, although 
the gene for mycosin-1 is present in the genome of this organism. This gene was found to be 
situated 3700 bp from the RD1 deletion region (28). 
Moreover, recombinant Rv1979c has been identifies as an antigen capable to induce IFNγ in 
correlation with extent of lesions at necropsy (29). Finally, no information is available in the 
literature about the immunoreactivity of the other proteins identified as relevant in discriminating 
TB patient sera.  
Both genetic and environmental factors also influence the antibody response. For example, the 
varied antibody response to Mtb is managed by HLA types. That fact, therefore, that our pool of 
peptides identified in an population has strong diagnostic value also for another population with a 
different genetic background, suggest that these peptides may form the basis of a test that can be 
used independent of location. 
Our results, in accordance with those obtained by other investigators, confirmed higher sensitivity 
for the smear-positive patients than for the smear-negative patients (P<0.001), due probably to a 
greater exposure to antigens in patients with high bacillary loads (30, 31). However, in developing 
countries such as Morocco where TB disease is prevalent, serological tests might play a major role 
in the setting of the diagnosis of patients with suspect TB where acid-fast bacilli examination is 
negative. Our results showed that with the ELISA based on the peptide pool, TB can be diagnosed 
with 44% sensitivity in acid fast bacilli smear-negative TB patients. This results is interesting given 
the facts that the are no simple fast alternatives (e.g. culture takes 6 weeks) in these clinical settings, 
and even thought that x-ray is a standard tool of TB diagnosis it could be quit questionable in some 
cases (32). 
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Finally, it is worth to consider that in the study population with high TB prevalence we evaluated, 
all controls were TST-positive. Thus, the peptide based ELISA was able to distinguish between 
active and inactive tuberculosis infection, while other immunological based tests such as TST and 
gamma–interferon based assays are not capable (33, 34). Nevertheless it would be important to 
explore how the ELISA based on the peptide pool performs in recently exposed individuals as well 
as in subjects with cured tuberculosis or under chemotherapy treatment that are known to present 
high anti-Mtb IgG levels (35).  
In conclusion, with the limitation of the small study population evaluated, this study indicates the 
applicability of the combination of nine well-defined synthetic peptides to the serodiagnosis of 
active TB. Their use in an ELISA would be important because of their stability, reproducibility and 
capability to identify strong humoral immune responses in patients with active pulmonary TB. The 
Mtb-complex specificity of these peptides strongly encourages further evaluation of this pool of 
peptides as a reagent for TB-specific immunodiagnostic assays on larger study populations 
including other disease groups such as patients with pulmonary disease other than TB, or 
seropositive patients for HIV. 
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Table 1:  Demographic characteristics of the study subjects 
 
Study group Number Mean Age (years) 
Sex-ratio 
(M/F) Ethnicity 
First 
panel 
Pulmonary TB patients 20 39 (33-53) 1.22 Caucasians  
Healthy subjects (TST-) 10 30 (26-42) 1.00 Caucasians 
Second 
panel 
Pulmonary TB patients 
  TPM+ 
 TPM0 
 
31 
16 
 
35 (25-45) 
39 (28-51) 
 
2.1 
2.2 
North Africans 
Healthy subjects (TST+) 26 39 (34-48) 2.5 North Africans 
 
TP = Pulmonary tuberculosis, TPM+ = Smear positive pulmonary tuberculosis, TPM0 = Smear positive pulmonary 
tuberculosis, M/F = male /female, TST+ = Tuberculin Skin Test positive, TST- = Tuberculin Skin Test negative. 
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Table 2: List of the peptides used in this study. 
 
*Peptide epitopes starting from amino acid position 1 in the protein sequence where two Alanine were added to the N-
terminus of the peptide in order to increase binding affinity to the epitope. 
 
Protein Peptide Number Starting amino acid  Amino acid sequence 
 
Rv0418 
Pep1 at 1* AAMVNKSRMMPAV 
Pep2 at 216 IPVVSVTKSVGFQLRGQSGPTTVK 
Pep3 at 377 AGIERTFVAYLKMAGKTAQDT 
Rv0747 Pep4 at 1 MSWVMVSPELVVAAAADLAG 
Pep5 at 385 HTLQQDVINMVNDPFQTLTGRPLIG 
Rv0755c Pep6 at 107 VVHPAVVQANRVRTWLLAVSNVFGQ 
Rv0934 (PAP) Pep7 at 140 EHLKLNGKVLAAMYQ 
Rv0956 Pep8 at 12 ARLVVLASGTGSLLR 
Pep9 at 176 ETLHERIKVTERRLLVAAVAALATH 
Rv1114 Pep10 at 46 RDVVLDLLANLYQFPVV 
Pep11 at 60 FPVVTHDEVLRLVGRRRLWGRG 
Rv1382 
  
Pep12 at 8 GSLIFAAVLVMLIAVLARLMMRGWR 
Pep13 at 120 RGVAGKVVAGIGILAIRWRLPSGT 
Rv1434 Pep14 at 1* AAMRASPAERVDGAYAGAGPHTQSV 
Rv1582c (RFO-10) Pep15 at 143 SIYPIVQRELARQTGF 
Pep16 at 254 AIWRRIRVVPFEVVIPADEQD 
Rv1866 
Pep17 at 91 DRYRHLVALSITDFGAAGPRSSWRA 
Pep18 at 149 AAVQAAWAVLVAYFNRLRCGTGDY 
Pep19 at 222 DGYVRFCVMAPRQWRGLRRWLGEP 
Pep20 at 372 YPFEGLRILDLGIIVAGGELS 
Pep21 at 502 TRMGYGPLVRAATGVTRVWTSDEAQ 
Pep22 at 538 TTIFPDHVVGRVGALLALAALIHRD 
Pep23 at 568 AHVHISQAEVVVNQLDTMFVAE 
Rv1979c 
Pep24 at 138 LTFLGFIGVLLAINLFGNRAIKWAN 
Pep25 at 413 DKVLPLVAIVVSVGLAVSYD 
Pep26 at 466 HYYRIIRRVGDRPSTR 
Rv1983 Pep27 at 348 NGIVTAPTAVNVVLLSIPTSPFAI 
Rv1986 
Pep28 at 36 LPVVALCTVSDIVLIAAGIAGFGA 
Pep29 at 102 TPVRLAEVLVTCA 
Pep30 at 165 GRLRGLFTNPGSW 
Rv2994 
Pep31 at 13 IMIVSLGVTASSFLFINGVAFLIPR 
Pep32 at 56 PSWGLVVTMFAWGYLLDHVGERMV 
Pep33 at 98 HSLLWIGVFLFLGGMAAGGCNS 
Pep34 at 204 SPYRGSSILWRIHAASALLMMP 
Pep35 at 228 VTVTFMLVWLINHHGWSVAQ 
Rv3042c  Pep36 at 137 LELRVSVPPGCVGPLQIALTKVAAE 
Rv3219 Pep37 at 68 RALKRRNARTKAR 
Rv3619c Pep38 at 28 QAIISDVLTASDF 
Pep39 at 72 QKVQAAGNNMAQT 
Rv3736  ( 38 kD) 
Pep40 at 24 TLLRAAGVRDQDV 
Pep41 at 34 QDVGNYDAFISIRAAIRAIESA 
Pep42 at 145 VALGVIRLLLGADYAPLAVH 
Pep43 at 226 GIVESVRTIVRQLLPTGAATLNV 
Pep44 at 269 TFVILVDRVRKDVADRYLR 
Rv3872 Pep45 at 56 EGIQLLASNASAQ 
Rv3873 Pep46 at 68 TPMVVWLQTASTQAKTR 
Rv3874 (CFP 10) Pep47 at 54 AVVRFQEAANKQK 
Pep48 at 74 TNIRQAGVQYSRA 
Rv3875 (ESAT-6) Pep49 at 2 QQWNFAGIEAAASAIQGNVTSIHSL 
Pep50 at 65 NALQNLARTISEA 
Rv3878 Pep51 at 139 PRVVATVPQLVQLAPHAVQMSQN 
Pep52 at 216 GDVQPAEVVAAAR 
Rv3879 (UF) Pep53 at 135 TAINSLVTATHGA 
Pep54 at 325 PHVKPAALAEQPG 
Rv3883c (MycP1) 
Pep55 at 219 IDYAVNVKGVVVVVAAGNTGGDC 
Pep56 at 337 DDLVGAGVIDAVA 
Pep57 at 372 APYNVRRLPPPVVEP 
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Figure 1 : Graphical value representation of the optical density (OD)  
obtained for each peptide and sera from the first panel by ELISA showing the heterogeneity of the antibody responses 
in TB patients and healthy subjects against Mycobacterium tuberculosis peptides. 
Antibody level (OD):       O  OD<0.100 ;           0.100≤OD<0.200 and         0.  200≤OD. 
The right column shows the score value for each peptide obtained by unvariate regression analysis.   
 
 
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17 P18 P19 P20 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10
Pep01 8,712
Pep02 9,036
Pep03 6,935
Pep04 4,000
Pep05 10,429
Pep06 6,554
Pep07 5,915
Pep08 6,630
Pep09 11,983
Pep10 3,465
Pep11 9,500
Pep12 7,425
Pep13 4,641
Pep14 9,534
Pep15 0,226
Pep16 4,468
Pep17 7,321
Pep18 8,553
Pep19 11,350
Pep20 1,535
Pep21 8,779
Pep22 10,004
Pep23 5,479
Pep24 0,762
Pep25 3,903
Pep26 9,661
Pep27 9,177
Pep28 0,025
Pep29 4,919
Pep30 4,695
Pep31 1,107
Pep32 7,423
Pep33 2,150
Pep34 0,233
Pep35 4,480
Pep36 2,972
Pep37 1,994
Pep38 4,802
Pep39 6,744
Pep40 4,626
Pep41 4,241
Pep42 11,215
Pep43 8,342
Pep44 4,279
Pep45 6,368
Pep46 6,055
Pep47 1,520
Pep48 7,307
Pep49 0,367
Pep50 10,115
Pep51 12,128
Pep52 5,505
Pep53 10,054
Pep54 7,591
Pep55 9,162
Pep56 7,621
Pep57 9,988
Peptides TB patients Healthy subjects Score
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Figure 2: The ROC curve of the peptide Pep51 evaluated with the panel of TB 
and control sera from a low incidence country for TB. (AUC = Area under the 
curve)  
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Figure 3: The ROC curves of the peptide Pep51 and the 9-peptides pool 
evaluated with the panel of TB and control sera from a high incidence country 
for TB. (AUC = Area under the curve) 
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Figure 4: Box plot representation of the distribution of levels of antibodies (IgG) 
to the 9-peptides pool of Mycobacterium tuberculosis  in TB patients and 
healthy subjects originated from a high incidence country for TB. (Error 
bars : 95% confidence interval for mean).  
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A MODEL OF PHENOTYPIC SUSCEPTIBILITY TO TUBERCULOSIS: 
DEFICIENT IN SILICO SELECTION OF MYCOBACTERIUM TUBERCULOSIS EPITOPES BY 
HLA ALLELES 
 
Abstract.  
HLA-DR allelic variants have been associated with tuberculosis (TB) susceptibility in different 
populations with risk ratios of 3.7 to 7.2.We hypothesized that the genetic susceptibility to TB 
depends upon the reduced capability of HLA-class II alleles of TB patients to bind and select 
peptide antigen from the Mycobacterium tuberculosis (MTB) expressed genome. To test this 
hypothesis, we developed a software that can predict HLA-DR restricted epitopes within the whole 
MTB genome based on quantitative peptide binding matrices.We analyzed the number of MTB 
epitopes recognized in two previously described populations of TB patients and matched controls 
and in a control population comprised of individuals affected by a sarcoid-like granuloma induced 
by beryllium and by healthy exposed controls. The number of putative epitopes within the whole 
MTB genome which could be bound by any HLA-DR allele (HLA-DR immunome of MTB) was 
405,422 out of 1,304,277 possible 9-mers i.e., 31.08% of the global capability, instead of the 
expected 35%. When tested at an affinity level equivalent of the 1% of the best binder peptides, the 
HLA-DR alleles (HLA-DRB1*0801, *0802, *1401, *1501 and *1502) associated with TB 
susceptibility recognized a significantly lower mean number of MTB-epitopes (7,862±4,258) than 
the MTB-epitopes recognized by HLA-DR alleles (HLA-DRB1*0301, *0701, *1101, *1102, *1301 
and *1302) negatively associated 
with TB (11,376±1,984, p<0.032). The number of epitopes bound at high affinity out of the whole 
MTB genome by the combination of the two HLA-DR alleles carried by each individual was lower 
in TB patients [TB-population 1: 11,341±908 (mean+SEM); TB-population 2: 15,303±657] than in 
matched healthy controls (CTR-population 1: 13,587±605, p<0.03 vs TB-population 1; CTR-
population 2: 1,6841±555, p<0.04 vs TB-population 2). No difference was seen in individuals with 
the sarcoid-like granuloma induced by beryllium compared to the exposed healthy (beryllium-
hypersensitivity: 17,593+447; controls 18,014±421; p=0.57). The data suggest that HLA-DR alleles 
associated 
with susceptibility to tuberculosis may be endowed with a reduced capability to bind at high affinity 
T-cell epitopes and select them for antigen presentation. The same alleles may contribute to 
determine the reaction to mycobacteria in non tuberculous granulomatous disorders. (Sarcoidosis 
Vasc Diffuse Lung Dis 2008; 25: 21-28). 
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Key words: tuberculosis, susceptibility, HLA, epitope prediction, T-cell response, sarcoid-like 
granulomas 
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Introduction 
Classic tuberculosis (TB) epidemiologic studies indicate that the genetic background may play an 
important role in susceptibility to TB (1).With the expansion of molecular genetics studies, a large  
number of genes have been associated with TB, leading to think that susceptibility might be the 
result of an imbalance between the effects of susceptibility genes and of protective genes such as 
the natural resistance- associated macrophage protein Nramp1, the IFN-α receptor 1, the IL-12 
receptor β1 genes and the HLA genes. In this regard, a number of allelic variants of the HLA locus 
which have been associated with TB risk in population studies indicating DQB1*05, *06 and 
DRB1*08, *14, *15 and *16 as susceptibility genes with risk ratios ranging from 3.7 to 7.2, and 
HLA-DRB1*03, *07, *11 and *13 as “protective” genes (2-10). HLA genes code for surface 
receptors that are known to play a pivotal role in the generation of antimicrobial immunity (11). 
HLA class II proteins (HLA-DP, -DQ and -DR) bind peptides derived from the digestion of 
microbes in the phago-lysosome of antigen presenting cells, carry them to the cell surface and 
present them to cytokine-producing CD4 T-cells. Structure-function studies of HLA class II 
molecules have indicated that the selection of antigenic peptides by the HLA receptors is dictated 
by the chemico-physical interaction between the amino acid side chains lining receptor-like pockets 
on the floor of the HLA antigen binding groove and the the agretopes i.e., the aminoacid side chains 
of the antigenic peptides (12, 13). As most of the polymorphisms generating allelic variability of the 
HLA molecules code for aminoacid changes in the peptide binding groove’s pockets, each HLA 
allele will bind a unique set of aminoacid side chains hence selecting a discrete set of antigenic 
peptides for antigen presentation (14, 15). As a consequence, the ability of HLA alleles to select a 
peptide antigen repertoire from a given microbe for antigen presentation, hence to induce a 
protective immune response, may vary widely, leading to greater susceptibility to infection of the 
subjects carrying the HLA alleles less efficiently binding and presenting antigens (16). In this 
context though, since each individual coexpresses  at least 2 HLA-DR molecules on the cell surface 
of the APC, it is reasonable to think that individual susceptibility to infection shall be determined by 
the capability of each subject’s two HLA-DR molecules combined to recognize microbial antigen 
epitopes, rather than the carriage of a single susceptibility allele. Moreover, among the HLA-DR 
alleles, there is a predominant expression of HLA-DRB1 alleles, being expressed at a level five 
times higher than its paralogues DRB3, DRB4 and DRB5 (17-19). The assessment of HLA-
associated susceptibility to TB, as model for susceptibility to granulomatous disorder mediated by 
mycobacteria, might thus require an analysis of disease associated phenotypes instead of disease 
associated alleles. To assess this hypothesis, we took advantage of bioinformatics tools allowing the 
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identification of antigenic peptides in whole microbial genomes by quantitative peptide binding 
motifs analysis for the HLA alleles (20). We developed software that can predict HLA-DR 
restricted epitopes in the whole MTB genome based on quantitative implemented peptide binding 
matrices and used this tool to determine the number of epitopes potentially recognized in the MTB 
genome in two already described populations of TB patients and matched healthy controls (21, 22). 
In addition, a population of patients affected by the sarcoid-like granulomatous reaction induced  by 
beryllium and matched beryllium-exposed subjects (23). 
 25
Methods 
Patients’ characteristics: The study populations was composed by the TB patients and matched 
controls of two already described separate reports on the genetic susceptibility to TB in which 
HLA-DR high  resolution typing was available for all study subjects (21,22). A population of 
patients with beryllium hypersensitivity and matched beryllium-exposed unaffected subjects were 
used as disease control  population (23). They were 160 patients with tuberculosis (TBpopulation 
1), and 200 controls (CTR-population 1) (see table 1) included in the Kim HS et al. study (22) and 
the 127 patients with tuberculosis (TB-population 2) and 120 matched controls (CTR-population 2) 
included in the Vejbaesya S et al. study (21) (see 22 A model of phenotypic susceptibility to 
Tuberculosis (table 1). The disease control  population included 74 subjects with beryllium 
hypersensitivity (BeH) and 86 beryllium exposed matched controls (Be-CTR) from the Amicosante 
et al. study (23). The quantitative implemented peptide binding motifs are available only for 52 over 
more than 300 HLA-DRB1 alleles (24, 25). All together they may cover, with at least one allele, 
about 90% of the HLA-DR variability of different human populations (26). For the purpose of this 
study, only the subjects carrying both HLA-DR alleles with an available HLA-DR binding motif 
were used (see table 1). Specifically, 106 out of 320 (33%) control subjects and 85 out of 287 
(30%) TB patients could be subjected to the analysis, as 168 (52%) controls and 151 (53%) TB 
patients had only one HLA-DR allele with  an available binding motif, while 48 (15%) controls and 
51 (18%) TB patients had both HLADR alleles without an available binding motif. Consequently, 
the alleles which were analyzed in the study populations were: HLA-DRB1* 0101, 0102, 0301, 
0401, 0402, 0404, 0405, 0408, 0410, 0701, 0802, 0806, 1101, 1102, 1104, 1106, 1301, 1302, 1307, 
1401, 1501, 1502. The selected subgroups did not differ for demographical characteristics from the 
subgroups of subjects excluded from the study for having one or both HLA-DR alleles without a 
known binding motif (data not shown). Genomes The genome of Mycobacterium tuberculosis 
H37Rv strain (NC 000962.2) composed of 4048 genes transcribed into 3,989 proteins and the 
genome of Escherichia coli K12 (NC 000913.2) were used in this study for the immuno-informatic 
analysis. Software for the identification and enumeration of epitopes in whole genomes To 
enumerate the T-cell epitopes present in data sets of proteins as large as a microbial genome, we  
eveloped a software for the identification and enumeration of peptide binding epitopes to HLA-DR 
molecules. This software was developed on LabView platform (National Instruments, US) using a 
graphic language. Basically, it is an open system in which two different databases are uploaded and 
crossed. Briefly, the first input database is represented by the protein sequences that can be 
uploaded from a file in FASTA format. The second database is represented by matrice(s) describing 
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the peptide binding capabilities of the HLA-DR alleles under analysis. The present version of the 
software is equipped with a set of 52 additional matrices for HLA-DR peptide binding profiles (15, 
27). 
The matrices database includes also the threshold values for different affinity levels as reported in 
the 
original packages. The distribution of the matrix results of all the 209 possible peptides that can  
theoretically bound HLA-DR molecule is automatically generated as well as theoretical affinity 
thresholds. The analysis can be customized by selecting single/multiple proteins and HLA alleles 
among the set of data loaded, threshold and other parameters. The software generates all the 
possible nonamer peptides in a protein sequence and analyse them on the HLA-peptide binding 
matrices in analysis. For each protein and each HLA allele, all the peptides presenting a permissive 
23 aminoacid (AA) in relative position P1 are stored in memory together with its matrix score and 
relative position in the protein. For the purpose of this work, two analysis were implemented in the 
software. A first analysis is represented by the identification of the epitopes recognised, in each 
single protein of the data set at the affinity threshold applied for each HLA-DR allele in analysis. 
This allows the enumeration of the epitopes in the whole data set and the identification and 
enumeration of proteins that present a defined number of epitopes, such as the proteins that are 
putatively not recognised by the HLA-DR allele at the affinity threshold used, as they present zero 
epitopes. A second specific analysis for the identification of the epitopes recognised in a set of 
proteins by 2 HLA-allelestogether has been developed to mime the situation of the HLA-DR 
recognition in a single subject. In this analysis, the software identify and enumerate the common 
and the different peptide epitopes recognised by the two HLA-DR alleles of the subject under 
evaluation by the position in the test set of proteins at the threshold of affinity applied. The whole 
MTB and E. coli genomes were analysed for the HLA-DR alleles negatively and positively 
associated to TB and for the enumeration of epitopes recognized by single subjects in analysis at the 
different thresholds of affinities equivalent to the 1%, 2%, 3%, 4% and 5% of the best binding 
natural peptides for HLA-DR alleles (27). The Threshold of affinity is a preselected numerical 
value used to differentiate between binders and non binders, any peptide frame scoring higher than 
this value is predicted as binder or vice versa; it correlates with the peptide score (15) and therefore 
with HLA-ligand interaction, therefore it is an indicator for the likelihood that predicted peptide is 
capable of binding to a given HLA-molecule. To express the results, we have chosen, the 
percentage of 1% in order to lower the false positive rate. The number of epitopes recognized by 
each study subject has been evaluated both as absolute number and as a relative number respect the 
amount of MTB epitopes in the whole genome. Statistical analysis All the data are expressed as 
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mean + standard deviation of the mean (SD). Comparisons between groups are made by Student’s t 
test. Results 1. The immunome of MTB H37Rv HLA-DR molecules bind a core of nine 
aminoacids long protein fragments, when they carry in the relative position 1 (hereafter named P1) 
non-polar residues (I, L, M, F, W, Y, V) i.e., 7 out of 20 aminoacids or 35% of all the aminoacids. 
Analysis of the genome of M. tuberculosis H37Rv strain (NC_000962), which comprises 4,048 
genes that can be transcribed into 3,989 proteins, allowed to estimate that, independently of the 
relative affinity of the epitopes for the HLA-DR molecules, the number of putative epitopes capable 
of binding any HLA-DR allele in the whole MTB genome was 405,422 out of 1,304,277 possible 9-
mers, that we define as the HLA-DR MTB-immunome. This indicates that the HLA-DR MTB-
immunome encompasses 31.08% of the whole MTB nonamer population. This number is 
equivalent to the 88% of the expected theoretical recognition that is equivalent to 35% of the all the 
peptides, thus suggesting that MTB encompasses a lower number of epitopes than expected if its 
genome presented a normal aminoacid distribution. Differently from MTB, the number of putative 
eepitopes capable of binding any HLA-DR allele in the E.coli genome was 537,294 out of 
1,566,080 nonamers (34.30%). This is equivalent to 98% of the expected theoretical recognition, a 
fraction that is significantly higher than that of the MTB HLA-DR immunome (p<0.0001). 2. 
Impaired MTB proteins recognition by HLA-DR alleles associated with TB susceptibility. HLA-
DR alleles HLA-DRB1*0801, *0802, *1401, *1501, *1502, which have been associated with TB 
susceptibility in previous studies, recognized significantly lower number of MTB-epitopes 
(7,862+4,258) than the HLA-DR alleles HLADRB1* 0301, *0701, *1101, *1102, *1301 and 
*1302, associated with TB resistance [11,376+1,984 (P<0.032)], at the affinity level of 1%. 
Consequently, there was a significantly higher number of MTB proteins (1,268+686) which could 
not be recognized by the HLA-DR alleles associated with TB susceptibility compared to HLA-DR 
alleles negatively associated with TB (776+232; p<0.001). 24 A model of phenotypic susceptibility 
to Tuberculosis 25 3. Phenotypic analysis of the ability of HLA-DR alleles of TB patients to bind 
whole MTB genome peptides. When this analysis was applied to those individual subjects carrying 
a pair of HLA-DR alleles with known peptide-binding motifs, the number of MTB epitopes 
recognized by TB patients in both populations was significantly lower than that recognized by 
controls [TB-population 1: 15,303±657, CTR-population 1: 16,841±555; p=0.038 compared to TB 
population 1; TB-population 2: 11,341±908, CTR-population 2: 13,587±605, p=0.035 compared to 
TB-population 2 (Figure 1 panel A)]. Interestingly, when a population of individuals affected by the 
sarcoid-like granulomatous reaction to beryllium was analyzed as a control, no differences where 
observed between granuloma-affected and unaffected subjects in their recognition ability of MTB 
genome peptides (beryllium-hypersensitivity: 17,593±447; beryllium-exposed controls 18,014±421; 
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p=0.608). Finally, when the the three population groups were tested for their ability to recognize E. 
coli genome peptides, no differences were seen between TB and their matched controls nor between 
Be-hypersensitive subjects and their matched controls (figure 1 panel B), suggesting that the 
epitope binding defect seen in TB patients was restricted to, or more pronounced for, the MTB 
genome. 
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Discussion  
The binding of antigenic peptides by the host HLA proteins expressed by antigen presenting cells is 
thought to represents a limiting step in the development of an antimicrobial immune response. In 
the 
context of the importance of HLA-DR genes in the immune response to MTB (28, 29) and of the 
observations positively or negatively linking different alleles of the HLA-DR, HLA-DQ, HLA-DP, 
and 
HLA class I genes to TB susceptibility in HLA association studies (10), it is reasonable to think that 
altered peptide binding by susceptible HLA molecules may be the cause of susceptibility to disease 
(11). 
With this as a background and in the context that TB susceptibility is increased in homozygous, 
compared to heterozygous twins (30), it is reasonable to hypothesize that a deficient antigen 
recognition capability of the immune system might be at the basis of the inefficacious response to 
MTB in susceptible individuals, and that the determinant of susceptibility to MTB infection and 
disease may be the combination of the recognition abilities of both HLA-DR alleles expressed by 
each subject, i.e., the HLA-DR phenotype. The finding of this in silico model that the number of 
MTB epitopes  ecognized by the combination of the two HLA-DR alleles by TB subject was 
significantly lower than the matched Fig. 1. Total number of epitopes recognized by M. tuberculosis 
and E. coli. The number of M. tuberculosis (panel A) and E. coli (panel B) epitopes recognised in 
silico by each study subject with the combination of the two carried HLA-DR alleles at the 
threshold affinity of 1% in the two genomes. The three populations evaluated (TB-population 1, 
TB-population 2, and Be-exposed control population) are presented separately. Open circles, 
control subjects; closed circles, TB patients; grey circles Be-exposed control population. p value has 
been determined by Student’s t-test. 26 S. Contini, M. Pallante, S. Vejbaesya, M. Hee Park, N. 
Chierakul, et al controls in both study populations suggest that TB patients present may be affected 
by a deficient capability of recognition of the MTB proteome compared to the non affected subjects 
in the population. Interestingly, Delgado et al. have recently reported a highly significant 
association between progressive pulmonary TB and homozygosity for HLADQ beta57-Asp alleles 
where a single polymorphism in the HLA-DQ beta chain played a critical role in the binding of 
ESAT-6, a highly immunogenic MTB protein and in the ensuing CD4+ T-cells immune response. 
Although they do not explain the mechanism of susceptibility to the development active TB, these 
data provided a functional link between an HLA polymorphism and susceptibility to progressive 
tuberculosis infection (31). In contrast to infection, current concepts are that in hypersensitivity and 
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autoimmune diseases susceptibility is associated with excessive HLA binding or the binding of 
specific (neo)-antigens by the HLA allele associated to the diseases (32). 
In this context, it has been shown that the immune reaction to non-tuberculous mycobacteria can 
be characterized by an exaggerated reaction leading to the hypersensitivity pneumonias of the hot 
tub 
lung (33), to the metalworking fluid-associated hypersensitivity pneumonitis (34), or to the 
formation of granulomas within the bronchial walls leading to the formation of bronchiectasis (35), 
a condition that’s been associated with HLA-DR 6, i.e., the alleles 13 and 14 (36). Mycobacteria 
have also been implicated in sarcoidosis, where acid fast rods have been seen in affected tissues 
(37), wall-deficient form (l-form) of mycobacteria have been isolated (38), and mycobacterial DNA 
has been detected (39). Interestingly, a reaction to mycobacterial antigens has been described in 
sarcoidosis as T-cell and antibody responses to MTB ESAT-6 and KatG protein (40), HSP70 (41), 
and superoxide dismutase (SodA) (42) have been observed in patients with sarcoidosis and some 
antigens such as the Heat Shock Protein (HSP) and Catalase-Peroxidase (KatG) have been detected 
by immunohistochemistry in sarcoid tissues (43, 44). It is worth noticing in this regard, that the 
same HLA allelic variants which have been associated with susceptibility or resistance to 
tuberculosis have also been implicated in susceptibility to sarcoidosis. The HLA-DRB1*03 alleles, 
which have been negatively associated with TB, being therefore dubbed as “resistance” genes (45), 
have been associated with acute, self limiting, sarcoidosis (46). In contrast, the HLA-DRB1*15 
alleles, which have been associated with the susceptibility to develop active TB (45), have been 
associated with stage III, or chronic sarcoidosis (47). Thus, one might hypothesize that the lack of 
HLA binding and presentation of mycobacterial antigens could determine disease progression in 
tuberculosis as well as in sarcoidosis, the type of reaction –extensively necrotizing versus non-
necrotizing, being possibly driven by the expression of allelic variants of the host’s genes of the 
innate immune response (48) or by variants expressed in the infected organism of the parasite 
virulence genes (49). The virtual approximation to truth made by in silico models, together with the 
limitation imposed by the reduced number of HLA-DR phenotypes that can be analyzed in the 
different populations, require that in silico results be confirmed by studies using  conventional 
biological techniques. With this caveats, is counceivable that the use of immuno-informatic tools 
for the prediction of T-cells epitopes also on other HLA class I and II alleles on data sets as large as 
an the entire MTB genome, will help with generating mechanistic hypothesis on the determinants of 
HLA-associated genetic susceptibility to TB, as well as to other granulomatous disorders caused, or 
induced, by mycobacteria. 
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DESIGN OF IMMUNOGENIC PEPTIDES FROM M. TUBERCULOSIS 
GENES EXPRESSED DURING MACROPHAGE INFECTION 
 
Abstract 
In vitro diagnosis of MTB-infection uses MTB proteins coded for by genes of the region of 
differentiation 1 (RD1) of the MTB genome. This study wants to test if proteins preferentially 
expressed by during MTB intracellular growth might provide new targets for the diagnosis of MTB 
infection. 
To this end Seventy-five multiepitopic HLA-promiscuous MTB-peptides were designed by 
quantitative implemented peptide binding motif analysis from 3 MTB-protein genes expressed in 
activated human macrophages (MA), 4 genes expressed during growth in non-activated human 
macrophages (MN-A), 12 housekeeping genes (HKG) and 6 genes of the RD1 region (RD1) as 
control. ELISpot for IFN- was performed to measure the responses of PBMCs deriving from 45 
patients affected by active Tuberculosis and 34 controls. In active TB patients, the mean response to 
RD1 derived peptides was higher than that to either MA (p<0.01), MN-A (p<0.008) or HKG 
(p<0.01) derived peptides. In TST-positive subjects all selected peptides elicited significant IFN- T-
cell responses (p<0.02 compared to TST-negatives), but without differences between the subgroups. 
Further, T-cell responses to RD1 peptides were lower in the 23 active-TB treated patients than in 
the untreated ones (p<0.01). The response to MA peptides in treated active-TB was higher than 
when untreated (p<0.01). These results demonstrate that the use of in vitro models of MTB-
intracellular infection to select MTB gene products for further in silico and in vitro assessment of 
their immunogenicity has the potential to identify novel antigens amenable to the design of new 
tools for diagnosis and monitoring of tuberculosis. 
 
KEYWORDS: 
Tuberculosis, peptide binding motifs, ELISpot, macrophage-induced mycobacterial genes. 
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INTRODUCTION 
Mycobacterium tuberculosis (MTB) is a facultative intracellular pathogen endowed with the ability 
to adapt to different growth milieus, either in cell culture or synthetic media, by altering its 
transcriptional profile1,2,3. The ability of MTB to evoke a strong type-1 immune response, hence 
allowing the rapid detection of MTB-specific interferon-gamma (IFN-γ producing T-cells, has been 
exploited to design in vitro diagnostic blood tests for MTB latent infection (LTBI)4,5,6. Following 
the demonstration that proteins coded for by genes of the region of differentiation 1 (RD1) of the 
MTB genome i.e., the early secreted antigenic target 6-kDa protein (ESAT-6) and the culture 
filtrate protein (CFP-10), can stimulate IFN- γ release by blood T-cells in 81 to 97% of tuberculosis 
(TB) affected individuals, IFN- γ -based blood tests have been designed for the diagnosis of 
LTBI4,5.  In this context, it is reasonable to hypothesize that proteins preferentially expressed by 
MTB in models of intracellular growth and infection might be ideal targets for the design of new, 
highly sensitive diagnostic tests of MTB infection and, possibly, for vaccine design1,2. However, a 
strong limitation in evaluating the efficacy of T-cell response-based assays is represented by the 
restriction of the host HLA haplotypes7. The “reverse immune-genetics” approach by using the 
quantitative implemented HLA peptide-binding motifs has been successfully applied for the 
identification and selection of HLA-restricted peptide epitopes8,9. It is worth noticing that the 
peptide binding motifs are now available for a large number of HLA alleles covering more than 
90% of the HLA haplotypes present in different human populations4,10,11,12.  The present study was 
designed to determine whether the selection of MTB proteins upon their expression in different 
conditions of intracellular growth in in vitro models might help with the identification of 
immunogenic epitopes amenable to in vitro diagnosis of LTBI. To this end, a panel of HLA-
restricted, promiscuous multiepitopic MTB-peptides, identified by quantitative implemented HLA 
peptide-binding motifs, has been evaluated in a study population including subjects of MTB 
exposed and not-exposed controls, BGC and not-BCG vaccinated, and patients with active TB. 
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MATERIALS AND METHODS 
Study design 
To measure the ex vivo immune response to the products of MTB genes expressed within activated 
and non activated human macrophages, or belonging to RD1 proteins, as control, a set of antigenic 
peptides were designed by bioinformatic analysis and tested in patients with active tuberculosis as 
well as in subjects infected and not with MTB. These responses were also measured in active 
tuberculosis during standard chemotherapy.   
Study population 
The study population included 22 patients with newly diagnosed, untreated active pulmonary TB 
and 23 TB patients undergoing standard treatment for 2 to 4 months, 10 of whom were evaluated 
both at presentation and after 2 months of treatment. Thirty four healthy individuals, 9 tuberculin 
skin test (TST)-negative subjects without any history of TB exposure (hereafter referred to as TB 
unexposed controls) and 25 TST-positive health-care workers, with a history of previous or current 
professional exposure (hereafter referred to as TBexposed controls) were also evaluated. Subjects 
were recruited at the Division of Respiratory Diseases of the University of Rome “Tor Vergata” at 
the Spallanzani Hospital of Roma 
(Italy), the Forlanini Hospital of Rome (Italy) and at the National Center of Infectious and Parasitic 
Diseases (University Hospital for Lung Diseases "St. Sofia"; Sofia, Bulgaria) after informed 
consent. The diagnosis of active TB was confirmed by M. tuberculosis culture isolation in all cases. 
A detailed analysis of the main demographic features, including the BCG vaccination status and the 
TST results, of each study group is shown in Table 1. An EDTA-peripheral venous blood sample 
was collected from all the participants of the study.  Epitope prediction and design of antigenic 
peptides Epitope prediction and design of antigenic peptides was performed by quantitative 
implemented HLA peptide-binding motif analysis as previously described 8 with minor 
modifications. Briefly, the sequence of MTB proteins belonging to the RD1 genomic region13   and 
of proteins expressed during MTB growth in human macrophage1,2, was obtained using the Swiss-
Prot database. Each protein sequence was then analyzed by quantitative implemented HLA peptide-
binding motif analysis using the ProPred database (http://www.imtech.res.in/raghava/propred/page2.html)10, 
which allowed the identification and scoring of all putative epitopes for any of the 51 considered 
HLA-class II alleles. Finally, to verify the specificity to MTB, the sequence of each pre-selected 
peptide was screened for homology of all known protein sequences using BLAST 
(http://www.ebi.ac.uk/blast/) through the selection of peptides that are restricted to the MTB complex 
with an identity higher than 85% respect to other mycobacteria* and higher than 75% respect to 
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other microbes. Table 2 shows the list of the peptides evaluated in the study. Each selected peptide 
included: (i) one or more epitopes able to bind at least four different HLA-DR alleles, with a 
putative binding capability equivalent to that of the 3% of the best binding peptides for any allele 
belonging to a given HLA-class II specificity and (ii) a flanking region of 2 aminoacids at the N- 
and C-terminus to increase the peptide binding affinity14. 
Peptides 
Designed peptides were synthesized by Fmoc chemistry as free amino acid termini with ABI 
technology (http://www.abi.it/). All peptides were purified by reverse-phase chromatography * At the 
time of the selection analysis the Mycobacterium marinum, Mycobacterium ulcerans and 
Mycobacterium smegmatis genomes were not available yet. However, the homolgy data presented 
in table 2 report also the identity to these mycobacteria although for some peptides the homology is 
higher than the 85% used as threshold during the selection steps.  (RPC) to >90% purity. The 
sequence and purity were confirmed by mass spectrometry and analytical RPC. Lyophylized 
peptides were diluted in DMSO at stock concentrations of 10 mg/mL for each peptide and stored at 
– 80°C till use. 
Cell isolation and culture conditions 
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll separation and resuspended 
in complete medium [RPMI, 10% heat inactivated fetal calf serum (FCS), 10 mM HEPES, 2 mM L-
glutamine and 10U/ml penicillin-streptomycin, all from Euroclone Ltd, United Kingdom]. Then, 
2x105 PBMCs per well were incubated in duplicate in a 96-well plate and stimulated with: (i) 
10µg/ml PPD (batch RT47; Statens Serum Institut, Copenhagen, Denmark); (ii) 5µg/ml 
Phytohemagglutinin (PHA) (Sigma, St Louis, MO, USA); and (iii) 18 pools of the 75 selected 
peptides. Briefly, to assess the T-cell response to a given peptide, 18 pools was prepared in a square 
matrix fashion set up with 9 rows and 9 columns pools. Each pool was prepared to contain 8 or 9 
peptides (a part pool 9 that contained only 2 peptides) so that each single peptide (final 
concentration of 5µg/ml) was tested in two different pools, once in a row-grouped pool and once in 
a column grouped pool in order to determine the specific contribution to the T cell response of each 
single peptide as previously described15. Both unstimulated and DMSO-treated (at the same 
concentration present in the peptide solution) PBMCs were included as negative controls. Data 
were rejected if the sum of the peptide pool result in in columns and in rows of the square matrix 
presented a difference above 10%. Evaluation of peptide specific single T-cell IFN-γ release. The 
enumeration of peptide specific T-cell producing IFN-γ was performed at the single cell level using 
a ELISpot assay, as previously described8. The number of spot-forming cells (SFCs) was measured 
in each well using an EliSpot reader (AID EliSpot reader system ELR03; Autoimmune Diagnostika 
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GmbH, Strassberg, Germany). Evaluated spots had a size >15U (1U=500µm2). The average number 
of SFCs of duplicate wells was then calculated and the value of appropriate controls subtracted 
from the SFCs of the stimuli. The absolute value of the SFCs for a single peptide was obtained by 
resolving the square matrix with the tested peptide pools as previously described16. Further, in some 
subjects the response to single peptides were tested individually to confirm the results of the matrix 
analysis method. An overall concordance above 90% between the methods were observed. 
Statistical analysis Data are expressed as the mean + standard deviation (SD). Comparison between 
groups was made using Mann-Whitney tests. A p value below 0.05 was considered significant. All 
tests 
were performed using the GraphPad Prism 4.0 (Graphpad software, San Diego, CA, USA) software 
package. 
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RESULTS 
Peptide selection 
Out of 25 MTB proteins, three expressed during growth in activated human macrophages (hereafter 
grouped as MA), four expressed during growth in non-activated human macrophages (hereafter 
grouped as MN-A), twelve coded for by constitutively expressed housekeeping genes (hereafter 
grouped as HKG) and six RD1 region proteins (hereafter grouped as RD1, which were used as 
comparators), 75 peptides were selected and used in this study (table 2). Specifically, 8 peptides 
were selected from the MA, 5 peptides from the MN-A, 47 from the HKG and 15 from the RD1 
proteins respectively (Table 2). Each peptide contain one or more HLA-DR restricted epitopes 
(Table 2). Each peptide, in its overall sequence, is predicted to bind HLA-DR alleles belonging at 
least to three different serological groups of HLA-DR1, 3, 4, 7, 8, 11, 13 and 15, with an affinity 
equivalent or higher than the 3% of to the best binder epitopes known for the HLA-DR alleles 
themselves (Table 2). Further, BLAST analysis for these multiepitopic peptides reveals a sequence 
identity with other mycobacteria varing from 100% to lower than 50% with an identity respect to 
other bacteria and viruses lower than 75%. Analysis of human T-cell responses to in silico selected 
peptides To evaluate the cell-mediated immune response to in silico selected peptides, the number 
of IFN-γ producing peptide-specific T-cell precursors in PBMCs of subjects with active pulmonary 
TB, in comparison with MTB-exposed and non-exposed healthy controls were determined by 
ELISpot. Further, the effect of standard chemotherapy on the response against these peptides were 
assessed. In its overall, 16 out of 75 peptides (n: 6, 7, 21, 25, 26, 28, 29, 33, 34, 38, 39, 40, 41, 49, 
59 and 66) did not show any significant difference of response between the three study groups. For 
the remaining 59 peptides, patients with active TB and TB-exposed controls presented a mean 
number of SFU/million PBMC significantly higher than the TST-negative controls (Figure 1). 
Analysis of T-cell responses to selected peptides in active TBpatients as positive control. The T-cell 
responses in active TB subjects presented a greater intensity of response compared to MTB-
unexposed controls [TST-negative 1.4+2.1 mean spots per peptide/million PBMCs; active-TB 
12.6+9.8; p<0.006 (Figure 1, panel A)]. Further, in active TB patients, the average intensity of the 
responses to either MA (7.1+3.5), MN-A (6.9+1.1) or HKG (8.2+3.2) derived peptides was lower 
that that of RD1 derived peptides (21.3+10.8; p<0.01 all comparisons) (Figure 1, panel A). Analysis 
of T-cell responses to selected peptides in TB-exposed subjects. TST-positive controls, elicited a 
significantly higher IFN-γT-cell responses against the in silico selected peptides (MA 7.6+3.5; MN-
A 8.9+3.5; HKG 7.9+4.5; RD1 12.9+6.8) than TST-negative (p<0.02; Figure 1, panel B). As 
already shown with ESAT-6 and CFP-10 multiepitopic promiscuous peptides15,17 the average 
 40
intensity of the T-cell responses to RD1 derived peptides was lower in TB-exposed TST-positive 
subjects (12.9+6.8) i.e., in the LTBIaffected, compared to active-TB patients (21.3+10.8; p<0.003). 
To the contrary, there was no difference in the response to MA, MN-A and HKG derived peptides 
in the TST-positive compared to the active TB patients affected (p>0.05, all comparisons). Analysis 
of T-cell responses to selected peptides during the course of active TB. In the context of the 
observation that the response to ESAT-6 and CFP-10 multiepitopic promiscuous peptides in active 
TB patients declines during chemotherapy18, T-cell responses to the MA, MN-A and HKG derived 
peptides were also analysed in subgroups of untreated and of treated active-TB patients, as well as 
in a selected group of active TB patients which were tested before and after two months of standard 
chemotherapy. As expected, the T-cell responses to RD1-derived peptides were higher in the 22 
untreated active-TB treated patients (mean total RD1 peptides SFC 251+116) compare to the 23 
chemotherapy treated ones (mean total RD1 peptides SFC 155+129, p<0.01 compared to untreated 
patients). Strikingly, we found an increased response to MA peptides in chemotherapy treated 
patients (mean total MA peptides SFC 121.8+44.6) compared to the untreated (mean total MA 
peptides SFC 52+29; p<0.01), while no differences were found for the MN-A (untreated active-TB 
mean total MNA peptides SFC 38+12; active-TB treated 33+9; p>0.05) and HKG- derived peptides 
(untreated active-TB mean total HKG peptides SFC 389+45; active-TB treated 306+78; p>0.05). 
This observation was confirmed in the ten active TB patients which were followed up during the 
two months of chemotherapy treatment. In eight out of ten patients IFN-γ release in response to 
RD1-derived peptides markedly declined over time (figure 2 panel A, p<0.02). Instead, it did 
strikingly augment in 9 out of ten (figure 2 panel B, p<0.01) in response to MA-derived peptides. 
As above, no change was seen with MN-A or HKG-derived peptides (p>0.05, all comparisons). 
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DISCUSSION 
The finding that the measure of IFN-γ-release as marker of type-1 immune response, in response to 
MTB-proteins is capable of identifying subjects with MTB-infection, either latent or active, has led 
to the  production of a number of tests such as the RD1-derived antigen based ELISA “Quantiferon-
TB” and the ELISpot “T-spot TB” tests. These tests, that are endowed with sensitivities ranging 
from 81 to 97% in the identification of patients with active MTB proliferation in tissue lesions19, 
have spurred microbial immunology and molecular biology research into MTB immunogenic 
proteins. However, critical aspects in this context are represented by the choice of immunodominant 
and specific antigens and, for T-cell response evaluation, in the restriction imposed by the patients' 
HLA background. In this context, the use of synthetic peptides in TB has been successfully 
demonstrated for diagnostic applications in  humans20,21,22. Overlapping synthetic peptides covering 
the entire sequence of a protein have been used to identify the peptides recognized by T-cells20,23. 
However, Since Th1 cells recognize mycobacterial antigens and epitopes in association with MHC 
class II molecules24 an alternative approach has been to screen proteins for identification of regions 
that can associate with MHC molecules25 and then test the peptides predicted to bind the MHC 
molecules for T-cell reactivity. Such approach has been shown to reduce drastically the number of 
peptides to be testes and thus the cost to screen for T-cell reactivity. Although several prediction 
programs have been proposed to identify peptides capable of binding to MHC class II molecules, 
recently a virtual matrix-based prediction server (ProPred) has been described, which can predict 
the binding capability of peptides to 51 HLA–DR alleles and has been shown to identify epitopes 
with a confidence of 95%10.  Although these prediction systems are far to be fully precise, the result 
of this study confirm that the in silico selected HLA-promiscous multiepitopic area of proteins can 
be the region presenting the highest capability of immuno response17, as shown comparing the 
result of this study with classic epitope mapping for some of the RD1 proteins such as ESAT-6, 
CFP-10, Rv3873 and Rv387826,27,28,29. Furthermore, previous studies from our laboratories have 
shown that MTB is capable of expressing differential transcription programs in response to different 
environments. In particular, MTB can express starkly different gene sets in synthetic media 
compared to macrophage cultures. RD1 proteins are expressed both in early and late phase cultures, 
are variably expressed in in vivo in murine models, but are expressed at very low level in 
macrophage cultures1,2,30,31,32,33.. 
With this background, we hypothesized that the MTB proteins expressed at the highest level in 
macrophage cultures could induce a stronger T-cell response in MTB infected subjects. The result 
of this study show that a group of peptides derived from a panel of MTB proteins selected for their 
expression in macrophage cultures are highly immunogenic, as they seem capable of eliciting Th1 
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T-cell responses in LTBI affected subjects that are as high as those elicited by RD1 derived peptides 
i.e., the present day diagnostic standard. A number of studies have analyzed the in vivo or ex vivo 
mycobacterial gene expression profile17. However, the inter-relationship between RNA and protein 
expression profiles, immunogenicity, either in silico or in vitro of the expressed proteins and the 
induction of Tcell responses has not been yet investigated in sufficient depth. Further, this study 
confirm the immunogenicity of the RD1 proteins in their overall and not only confined to ESAT-6 
and CFP-10. In fact, only 4 out of the 15 RD1 derived peptides were designed on ESAT-6 and 
CFP10 and these peptides account only for 19-43% of the response to the whole RD1 peptides (data 
not shown). Furthermore, this study identified 19 proteins which elicit a strong T-cell response in 
LTBI and TB affected subjects as high as in RD1 peptides. However, few of these proteins have 
been characterised so far. Specifically, none of the MA proteins has been immunologically 
characterized. The MA proteins: Rv3042 and Rv1114; the M-NA proteins: Rv0198c, Rv1382 and 
Rv0755; the HKG proteins Rv1582, Rv0418, Rv1434, Rv1866, Rv0956 and Rv3219 have not yet 
been cloned and expressed for biochemical and functional studies34. The MA protein Rv3883c 
(MycP1) is a membrane-anchored mycosin serine protease35 and Rv3042 (serB2) is a phosphoserine 
phosphatase34. The only characterized M-NA protein is Rv0125 (PepA), another protein belonging 
to the MTB serine protease gene family, is also known as MTB32A and has been found in culture 
filtrates. Consistent with our data, PepA is immunogenic as it has been shown to elicit memory T-
cell responses in latent and active TB36,37. Among the 12 HKG proteins evaluated in the study, three 
are known to be immunogenic in an animal model and two in an in silico model. Rv1979c and 
Rv1986, that’s belong to the RD2 gene region and Rv1769 that’s belong to the RD14 gene region, 
have been shown to elicit effector T-cell responses in 59-86% of M. bovis-infected and/or BCG-
vaccinated cattles38. Interestingly, two other HKG gene products, Rv1983 and Rv0747, belong to 
the PE-PGRS gene family34 i.e., a multigene family that, together with the PPE gene family, makes 
up about 10% of the MTB genome and whose gene products comprise an extraordinarily high 
number of peptides displaying high-affinity for HLA class I alleles in silico39 supporting the 
hypothesis of their  immunogenicity and potential role in immunodiagnosis as suggested by our 
data by the reports on other proteins belonging to these multigene families10,40,41. Further, the 
comparison between the time course of the responses elicited by the MA, MN-A and the HKG 
derived peptides and that against RD1-derived peptides in active TB patients, whereby the response 
to RD1 peptides declines with the reduction of active lesion subsequent to treatment, may suggest 
that the IFN-γ response to certain RD1 peptides may be mycobacterial load, hence antigen 
concentration, dependent and may wane with the its rapid mycobacterial load reduction achieved by 
standard chemotherapy15,18. Interestingly, the response to MA, MN-A and the HKG derived 
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peptides seems to be more stable or may increase with time, as shown for MA-derived peptides. In 
conclusion, the results of our study suggest that promiscuous peptides capable of Th1 cell reactivity 
in HLA heterogeneous population can be predicted from the in silico HLA-DR 
binding analysis of complete proteins overexpressed in model M. tuberculosis infections in 
macrophage. It has been predicted that the number of putative T-cell epitopes in M tuberculosis are 
about 1,500,000, which can be reduced effieciently reduced to few hundreds peptides by identifying 
proteins overexpressed during MTB infection in human and prescreening the coding sequences for 
HLA-DR binding using the prediction programs. This has the potential to identify novel antigens 
eventually be amenable to the design of new diagnostic tools. 
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Figure 1. 
 
IFN-γ  response to the 75 multiepitopic HLA promiscuous MTB peptides obtained from 24 MTB 
proteins. Each column represents the enumeration of IFN- γ producing cells induced by one 
selected peptide. The measurement was performed by a ELISpot assay in active TST-negative 
(panel A), TST-positive (panel B) and TB patients (panel C). Data are reported as the mean of the 
SFCs per million PBMCs for each peptide. Peptides are grouped as belonging to genes expressed in 
activated human macrophages (MA), expressed during growth in non-activated human 
macrophages (MN-A), housekeeping genes (HKG) and RD1 region (RD1). Black bars represent 
peptides showing responses with significant differences between the three study groups (p<0.05) 
while open bars represent those did not. Peptides drived from CFP-10 (*) and ESAT-6 (§) are 
represented in the last four positions. 
 
 
 48
Figure 2.  
 
Evaluation of the in vitro response to RD1 derived peptides (panel A) and to peptides designed 
from genes expressed in activated human macrophages (MA, panel B) at the time of diagnosis of 
active-TB and after 2 months of standard anti-tuberculous therapy in a subgroup of active-TB 
patients. Each study subject is represented by one line and the ordinate represents the sum of the 
number of IFN- γ producing spot forming cells (SFC) per million PBMCs in response to the 
peptides of each group. 
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Table1. Study group 
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Table2. List of the selected peptides 
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Notes: 
|| Peptides are grouped according to the capability of the belonging protein to be selectively over 
expressed during growth in activated human macrophages (MA), expressed during growth in non-
activated human macrophages (MN-A), constitutively expressed housekeeping genes (HKG) and 
belonging to the RD1 region proteins (RD1). 
*Peptide epitopes starting from aminoacid position 1 in the protein sequence where two alanines 
were added to the N-terminus of the peptide in order to increase binding affinity (see also Method 
section). 
§Peptide sequence reported as single letter code. The underlined letter(s) in the peptide sequence 
indicate the aminoacid acting as P1 of the epitope(s) presented along the peptide sequence as for 
quantitative implemented peptide binding motif analysis. 
°HLA-DR group variants capable to bind in silico the peptide sequence with an affinity equivalent 
or higher than the 3% of the best binder peptides for the alleles present in the variant. 
^Homology analysis of the peptide sequence performed by BLAST reporting reported the first 
microorganisms not beloning to the M. tuberculosiscomplex with the higher percentage of identity 
(expressed as percentage) to the selected protein sequence. 
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IMMUNOGENETICS OF SARCOIDOSIS 
 
M. AVIUM BINDING TO HLA-DR EXPRESSED ALLELES IN SILICO: A MODEL OF 
PHENOTYPIC SUSCEPTIBILITY TO SARCOIDOSIS 
 
Abstract 
Sarcoidosis is a systemic granulomatosis disease of unknown origin where a number of 
microbes, in particular M. tuberculosis and non-tuberculous mycobacteria, have been hypotesized to 
play a role in disease pathogenesis, possibly through bacterial antigen-driven hypersensitivity. To 
test this concept, we used bioinformatic tools allowing the identification of antigenic peptides in 
whole microbial genomes to analyze the interaction between the expressed HLA-DR gene allelic 
variants and the HLA-DR immunome of all pathogenic bacteria in a population of 149 sarcoidosis 
affected subjects and 447 controls, all  HLA-typed at high resolution.  
 We show here that patients with the Loefgren’s syndrome, express HLA-DR alleles that 
recognize in silico a significantly higher number of bacterial antigen epitopes compared to the 
control population (18,496+9,114 vs 17,954+8,742; p<0.00001), and the chronic sarcoidosis 
affected popuation (17,954+8,742; p<0.00001 vs Loefgren’s and controls). Further, the analysis of 
the ability of the HLA-DR allele combinations expressed by the Loefgren’s and the chronic 
sarcoidosis affected subjects to recognize M. avium epitopes demonstrates that a significantly larger 
number of Loefgren’s are capable of top affinity recognition, compared to chronic sarcoidosis (45% 
vs 17%, p<0.0037). Finally, both Loefgren’a and chronic sarcoidosis subjects expressed HLA-DR 
allele combinations capable of M. tuberculosis and M. avium epitope recognition at higher affinity 
than tuberculosis affected subjects (p<0.01 all comparisons). 
In conclusion, we propose that -- at least in a subgroup of affected subjects-- sarcoidosis 
might be part of a spectrum of granulomatous responses to several agents where the Loefgren’s 
syndrome represents the hyper-reactive end of the spectrum while pulmonary tuberculosis and 
atypical mycobacterial infections might represent the opposite end. 
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Introduction 
Sarcoidosis is a chronic disorder characterized by the accumulation of increased numbers of 
T-lymphocytes and activated mononuclear phagocytes in the lower respiratory tract and other sites 
of disease, leading to the formation of noncaseating granulomas in involved tissues such as the 
lung, skin and eyes. Several lines of evidence suggest that the accumulation of activated T-cells and 
macrophages in the lower respiratory tract is the result of chronic stimulation by some (yet 
unknown) antigen(s) (1). Firstly, in sarcoidosis activated alveolar macrophages possess increased 
ability of presenting antigens to T-cells (2) and express HLA-DR molecules at higher level at the 
surface of the cell (3). Secondly, T-cells accumulate in the lower respiratory tract where they 
release interleukin 2 (4, 5) and interferon-γ at exaggerated rates (2). Thirdly, sarcoid lung T-
lymphocytes display activated memory T-cell phenotypes (6, 7) and express oligoclonal Vβ T-cell 
receptor genes as they were locally expanded in response to a classical antigenic stimulus rather 
than a more broad-based stimulus such as from a superantigen (8, 9). 
A number of potential causation agents have been implicated in the pathogenesis of 
sarcoidosis (10) and some sarcodosis-like disease and reactions could be identified as 
hypersensitivities to compounds such as beryllium (11), titanium (12) , zirconium (13) and 
aluminum (14). Recently, it has been shown that, in addition to chemicals, microbial agents 
otherwise capable of causing infection and disease may be implicated in the pathogenesis of 
granulomatous hypersensitivity pneumonias such as the hot tub lung, where M. avium has been 
identified as a causative agent and (15) and metal working fluid pneumonitis, where a variety of 
bacteria have been implicated (16). Furthermore, in a chronic granulomatous disease such as 
Chron’s disease M. avium paratuberculosis has been implicated (17). 
In sarcoidosis, since the application of the the polymerase chain reaction to the detection of 
mycobacterial genomes in clinical samples (18),  the presence of  nucleic acids of M. tuberculosis, 
non tuberculous mycobacteria and of Propionibacterium acnes has been observed both in 
bronchoalveolar lavage and tissue samples in different sarcoidosis patient populations (19-23). 
Collectively, these studies indicate that mycobacteria can be found in tissue samples in 23 to 30% 
of sarcoid patients, with a ten-fold higher probability compared to controls, and suggest an 
association between mycobacteria and sarcoidosis (24-26).  
In this context and with the knowledge that certain microbial agents could cause 
hypersensitivity reactions leading to granuloma formation in the absence  of clinical infection, the 
observations that antibody and T-cell mediated immune responses against mycobacterial antigens, 
such as catalase-peroxidase (mKatG) (27), heat shock protein (Mtb-hsp) (28), and Antigen 85A (29) 
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could be demonstrated in sarcoidosis and in the Kweim reaction, led to hypothesize that  exposure 
to certain microbes might be causative of sarcoidosis in hyperreactive individuals (30-32). 
Antigen presentation to CD4 T-cells is mediated by a class of peptide cell surface receptors, 
the  HLA class II proteins (HLA-DP, -DQ and -DR), which are capable of binding peptides derived 
from the digestion of microbes and other agents in the phago-lysosome of antigen presenting cells 
and to carry them to the cell surface and to present them to the CD4 T-cell expressing the 
appropriate T-cell antigen receptor.  Importantly, the selection of antigenic peptides presented to, 
hence recognized by, T-cells is driven by the chemico-physical interaction between (i) the amino 
acid side chains which are lining the receptor-like pockets on the floor of the HLA antigen binding 
groove and (ii) the aminoacid side chains of the antigenic peptides (33, 34).   
The HLA class II genes have been implicated in susceptibility to sarcoidosis (35, 36) and it 
has been shown that the expression of different HLA allelic variants is associated with different 
clinical presentations and disease outcomes. The Loefgren’s syndrome, an acute form of sarcoidosis 
characterized by fever, erythema nodosum, bilateral hilar lymphoadenopaty and/or ankle arthritis is 
associated with the expression of the HLA-DRB1*0301 allele and has a favourable clinical 
outcome (37). On the other hand, chronic forms of sarcoidosis with less favourable outcomes have 
been associated with the expression of the DRB1*1501 allele (37).  
Key to the understanding of susceptibility to immune disorders is the knowledge that HLA 
alleles can select peptide antigens for antigen presentation with widely varying affinities, thus 
leading to different immune responses against the same agent.  In this regard, it is well known that 
since the HLA polymorphisms characterizing allelic variants code for aminoacid changes in the 
peptide binding groove’s, each HLA allele binds a unique set of aminoacid side chains. Each HLA 
class II allelic variant is therefore capable of selecting a discrete set of antigenic peptides for antigen 
presentation (38, 39) and to allow for the formation of unique HLA molecule/T-cell 
receptor/antigenic peptide complexes activating specific cytokine producing CD4 T-cells (40). 
Thus, since each individual coexpresses at least two HLA-DR molecules on the cell surface of the 
antigen presenting cell, it is reasonable to think that individual ability to generate immune responses 
to a given antigen shall be determined by the capability of each subject’s two HLA-DR molecules 
combined to recognize  antigen epitopes (41-43). 
By using bioinformatics tools allowing the identification of antigenic peptides in whole 
microbial genomes (44), we have recently demonstrated that the expression of HLA-DR allele 
combinations endowed with a lower affinity for the M. tubercuosis genome and for its derived 
peptide antigens is associated with susceptibility to active tuberculosis (45). Interestingly, the HLA-
DR alleles implicated in this reduced ability to bind and select for mycobacterial antigenic peptides 
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are the same which have also been associated with chronic sarcoidosis. Even more interestingly, the 
alleles endowed with higher affinity for M. tuberculosis antigenic peptides, and with “protection” 
against tuberculosis,  are the same which have been previously associated with the acute forms of 
sarcoidosis (45). 
With the background that the affinity for peptide antigens of the HLA-DR expressed allelic 
variants plays a key role in determining the ability of the individual to recognize and react to 
bacterial antigens, hence in generating the ineffective immune response leading to bacterial 
invasion and active disease, we hypothesized that it may also play a role in determining 
suceptibility to hypersensitivity reactions to the same bacteria. To test this hypothesis, we set out to 
to analyze the interaction between the expressed HLA-DR gene allelic variants and the genomes of 
all pathogenic bacterial in the Loefgren’s syndrome and in chronic sarcoidosis,  two 
immunologically contrasting forms of sarcoidosis, in order to determine whether hypersensitivity to 
mycobacterial, propionibacterial or other bacterial antigens may play a potential role in the 
pathogenesis of  sarcoidosis. 
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Methods 
Patients’ characteristics:  
The study population was composed by the patients with sarcoidosis and matched controls 
of an already described population evaluated for the genetic susceptibility factors in sarcoidosis. 
HLA-DR high resolution typing was available for all study subjects (35). 
They were 149 patients with sarcoidosis, of which 39 with Loefgren’s syndrome and 110 
with chronic sarcoidosis, and 447 matched controls (see table 1). The quantitative implemented 
peptide binding motifs  i.e., the algorithms with which to assess the ability of a given HLA-DR 
alleleic variant, are available only for 49 out of the more than 300 HLA-DRB1 alleles (46, 47) and 
cover, with at least one allele, about 90% of the HLA-DR variability of different human populations 
(48). For the purpose of this study, only the subjects carrying both HLA-DR alleles with an 
available HLA-DR binding motif were included (see table 1). Specifically, 349 out of 447 (78.1%) 
control subjects, 31 out of 39 (79.5%) patients with Loefgren syndrome and 93 out of 110 (84.5%) 
patients with chronic sarcoidosis, could be subjected to the analysis.  
The selected subgroups did not differ for demographical characteristics from the subgroups 
of subjects excluded from the study for having one or both HLA-DR alleles without a known 
binding motif (data not shown).  
Finally, a group of patients with active tuberculosis and matched controls already evaluated 
previously (45) were used as comparison. They include: (i) 303 patients with active tuberculosis of 
which 92 carrying both HLA-DR alleles with an available HLA-DR binding motif and (ii) 345 
controls of which 111 carrying both HLA-DR alleles with an available HLA-DR binding motif  
(Table 1). 
 
Genomes.  
One hundred and twenty four, non redundant, bacterial complete genomes, classified as 
“relevant human pathogens” in the Genome OnLine Database v2.0 (GOLD database update 
October 30th 2008, http://www.genomesonline.org/), were used to analyse the number of potential 
epitopes in each genome which were recognised by the study population. Bacterial genome 
characteristics (accession code, species, family, human disease and number of open reading frames) 
are listed in table 2. 
 
Software for the identification and enumeration of epitopes in whole genomes 
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To enumerate the T-cell epitopes present in the protein data sets of each microbial genome 
examined, we used a software specifically designed for the identification and enumeration of 
peptide binding epitopes to HLA-DR molecules in large set of protein databases,  as already 
described (45).  
For the purpose of this study, the bacterial genomes were analysed for enumerating the 
epitopes in silico recognised by the combination of the HLA-DR alleles carried by single subjects at 
an affinity level equivalent or higher than the 1% of the best binder peptides for the allele in 
analysis (49). The Threshold of affinity is a preselected numerical value used to differentiate 
between binders and non binders, any peptide frame scoring higher than this value is predicted as 
binder or vice versa; it correlates with the peptide score (39, 49) and therefore with HLA-ligand 
interaction, therefore it is an indicator for the likelihood that predicted peptide is capable of binding 
to a given HLA-molecule.  
 
Statistical analysis.  
All the data are expressed as mean + standard deviation of the mean (SD), and frequency 
expressed as percentage. Interquartile distribution of epitope number recognised was used to 
classify allele combination. Comparisons between means are made by Student’s t test. Comparison 
between frequencies is made by Chi-square, with Yates and Bonferroni’s correction, Chi-square for 
trend and Fisher’s exact test when appropriate. GraphPad Prism version 4.0 was used for all 
statistical analyses and graphs..  
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Results  
Differential capability of chronic sarcoidosis and Loefgren’s syndrome affected subjects to 
recognize genomes of human pathogen.  
The capability of the HLA-DR expressed allelic variants of the study subjects to bind 
bacterial peptide epitopes was determined as the number of epitopes bound in silico at the top 1% 
affinity.  At an affinity level equivalent to that of the top 1% of the binder peptides for the HLA-DR 
molecules of the study subjects, Loefgren syndrome affected subjects recognized a higher number 
of epitopes (mean epitope number for all the genomes: 18,496+9,114) than chronic sarcoidosis 
affected subjects (17,515+8,448; p<0.00001) and controls (17,954+8,742; p<0.00001). In addition, 
the comparison between chronic sarcoidosis and healthy controls showed that the capability of 
affected subjects to recognize bacterial pathogen genomes was significantly reduced compared to 
controls (p<0.00001). 
Interestingly though, the capability of the HLA-DR allelic variants expressed by Loefgren’s 
syndrome affected subjects to recognize a higher number of epitopes than chronic sarcoidosis 
affected subjects was not generalized to all the genomes examined, but it was more prominent for 
certain bacterial pathogens. In particular, statistically significant differences in the mean number of 
epitopes recognized by Loefgren syndrome affected subjects with respect to chronic sarcoidosis 
affected subjects was observed for the genomes of bacteria belonging to the genders Bordetella, 
Burkholderia, Granulibacter, Mycobacterium, Nocardia and Propionibactierium (table 2 and figure 
1). The largest difference was observed for Mycobacterium avium, where there was 12% difference 
between the average HLA-DR immunomes, i.e. the number of putative epitopes deduced from the 
whole bacterial genome that were capable of being bound by the HLA-DR expressed allele of each 
individual subject, of the two disease groups (figure 1).  
 
Contribution of the different HLA-DRB1 alleles combination in the hyper-recognition of genomes 
by patients with Loefgren’s syndrome.  
In order to analyze the nature of the exaggerated epitope recognition of bacterial genomes 
seen in the subjects with Loefgren’s syndrome compared to those with chronic sarcoidosis, the data 
obtained in the study population for the HLA-DR immunome of M. avium i.e., the best binder of all 
tested genomes, were used. 
The distribution of HLA-DR allelic variants in the study populations is shown in table 3. As 
previously reported (37), alleles HLA-DRB*0301 and *0407 were significantly more frequent in 
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the Loefgren’s syndrome affected while the allele *1501 was significantly over-represented in the 
chronic sarcoidosis affected group (table 3).  
Table 4 shows the distribution of M. avium genome recognition levels in the study groups, 
according to the percentile distribution from bottom to top recognition levels. Considering the 
affinity level equivalent to 1% of the higher affinity peptides, the 1,225 different combinations 
generated by the 49 HLA-DRB1 alleles for which the quantitative implemented peptide binding 
motifs is available, can recognize 6,149 to 43,781 epitopes in the genome of M. avium. Subjects 
with Loefgren’s syndrome showed significantly higher levels of M. avium epitope recognition than 
subjects with chronic sarcoidosis as 45% of the Loefgren’s affected were in the top 76-100° 
percentile compared to 17% of the chronic sarcoidosis affected (p=0.0037) and 26% of the controls 
(p=0.0386). Conversely, subjects with chronic sarcoidosis showed a significantly higher level of M. 
avium epitope recognition in the lower 26°-50° percentiles distribution with 39% compared to the 
16% of the Loefgren’s affected (p=0.0363) and the 24% of the controls (p=0.0059; table 4). 
Furthermore, in order to determine whether the exaggerated recognition of microbial 
genomes such as those of mycobacteria, shown by Loefgren’s syndrome affected subjects, was 
associated with the expression of specific HLA-DR allelic variants rather than with the expression 
of combinations of HLA-DR alleles endowed with higher binding capabilities, we analyzed the 
distribution of HLA-DR alleles in the M. avium recognition percentile subgroups. 
This analysis showed that there were no biases in the expression of HLA-DR variants in the 
Loefgren’s syndrome affected population, neither in the 26-50° nor in the 76-100° percentile groups 
(table 5). Only the association of the HLA-DRB1*1501 allele with chronic sarcoidosis remained 
statistically significant both in the higher and the lower affinity percentile groups (table 5).  
 
Assessment of HLA-DR M. avium and M. tuberculosis epitope affinity in sarcoidosis and 
tuberculosis.  
Altogether the data suggests that Loefgren’s syndrome immune responsiveness might be 
characterized by the expression of HLA-DR genomes endowed with an exaggerated ability to 
recognize bacterial genomes while, in contrast, chronic sarcoidosis appears to be characterized by 
the expression of HLA-DR alleles with significantly lower ability to bind and present bacterial 
antigens. As already reported in tuberculosis affected patients a biased expression of the same 
HLA-DR alleles expressed in sarcoidosis could be observed (45). 
Strikingly, the comparison of epitope binding affinity of the HLA-DR allelic combinations 
expressed by sarcoidosis affected subjects with those of tuberculosis patients showed a statistically 
significant lower binding affinity, both toward the M. avium and the M. tuberculosis immunomes 
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than that of sarcoidosis affected subjects. In addition, when the patient groups were ranked by their 
binding affinities, the Loefgren’s affected ranked the highest, with the tuberculosis affected the 
lowest. Chronic sarcoidosis, although ranking lower than controls ranked higher than tuberculosis 
(table 6), thereby indicating that in tuberculosis the susceptibility to infection and active disease is 
likely associated with the expression of a defective epitope recognition repertoire .   
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Discussion 
We show here that patients affected by the Loefgren’s syndrome express HLA-DR alleleic 
combinations that recognize a significantly higher number of bacterial antigen epitopes compared to 
healthy individuals, as they do in comparison to chronic sarcoidosis. 
With regard to sarcoidosis, the data are consistent with the observation of Grosser et al. (50) 
who recently reported the association of chronic sarcoidosis, the presence of mycobacterial DNA in 
affected tissue and the expression of DRB1*15, whereas acute sarcoidosis was associated with the 
absence of mycobacterial DNA and with the expression of HLA-DRB1*03. These data add further 
support to the concept that the manifestations and outcomes of sarcoidosis are driven by a complex 
interaction between antigen presentating molecules, antigens(s) and T.-cell receptors leading to 
antigen clearance or persistence (51). In this hypothesis, HLA Class II molecules with the higher 
affinity for mycobacterial antigenic epitopes might present to T cells wider antigen repertoires with 
more elevated efficiency. This would initiate a hypersensitivity response leading to acute onset of 
disease, antigen clearance and spontaneous disease remission. To the contrary, HLA Class II 
molecules, such as DRB1*1501, due to their lower affinity for bacterial epitopes, would express a 
less efficient antigen presentation process, thereby dictating a sluggish immune response resulting 
in insidious clinical presentation, antigen persistence, continuing granuloma formation: in summary, 
to chronic sarcoidosis.   
Following the same line of interpretation, also for the in silico data presented here on 
tuberculosis patients, our observation would suggests that patients bearing even less recognizing 
HLA-DR allele combinations could be unable to mount an effective immune response, would fail to 
achieve bacterial containment and would, consequentially, develop active infectiuos disease.  
Interestingly, it has been proposed that in tuberculosis a spectrum of immune reactions may 
be recognized, where poor cellular mediated immunity, associated with exuberant antibody 
production, represents one end of the spectrum while good cellular mediated immunity, with little 
or no antibody formation, would be at the other end (52). Similarly, in leprosy the immune 
spectrum is represented by non-reactive disseminated lepromatous leprosy, associated with HLA-
DR 15 alleles (53, 54), at one end, while tuberculoid leprosy --the disease presentation 
characterized by stronger T-cell mediated immunity and a lesser invasiveness—is associated with 
HLA-DR3 alleles (55) and represents the opposite end. In this context, it is enticing to hypothesize 
that sarcoidosis may be part of a spectrum of granulomatous response to one or more closely related 
bacteria where the Loefgren’s syndrome represents hypersensitivity, similarly to the hot tub lung 
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(15) and the metalworking fluid associated pneumonitis (16), while pulmonary atypical 
mycobacterial infection and tuberculosis might represent the other end of the spectrum. 
In conclusion, even though these in silico immunogenetic data still need to be confirmed in 
other sarcoid populations with different ethnical backgrounds and to be validated by in vitro and ex 
vivo confirmatory analysis, our findings support a pathogenetic role of specific groups of bacteria in 
the hypersensitivity granulomatous reaction(s) of sarcoidosis. 
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Figure 1. Relative recognition of all the Loefgren’s syndrome affected subjects with respect to 
chronic sarcoidosis patients of the HLA-DR immunomes deduced from the genomes of 
pathogenic bacteria. The ratio of the total number of the recognized epitopes (on the ordinate) 
in the two study groups is reported for 124 non redundant genomes of bacterial pathogens 
analysed (shown in alphabetic order on the abscissa). The bacterial groups showing 
statistically significant differences in HLA-DR immunome recognition are indicated on the 
graph. 
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Table 1. Study population. 
Study  
population Subject number 
Subjects with both HLA-DR alleles with 
known peptide binding motif1 
Controls 447 349 (78.1%) 
Loefgren 39 31 (79.5%) 
Chronic Sarcoidosis 110 93 (84.5) 
 
1. Numbers of subjects for each study population used for the epitope prediction analysis. 
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Table 2. List of non redundant, complete bacterial genomes classified as “relevant human 
pathogens” in the Genome OnLine Database and analysis of the number of potential epitopes 
in each genome recognized by the study populations. 
 
 
 
ORGANISM1 DISEASE 
GOLD 
DATABASE 
Entry 
Genome 
(Kb)2 
Number 
of 
ORFs3 
Mean Number of potential epitopes (1% 
affinity) in the study population4  t-test (p value)
5 
Controls Chronic 
sarcoidosis Loefgren 
Chronic 
Sarc vs 
CTR 
Loefgren 
vs CTR 
Loefgren 
vs 
Chronic 
Sarc 
Acinetobacter 
baumannii 
Meningitis, 
Pneumonia, 
Septicemia 
Gc00522 3976 3352 17871±3963 17460±3881 18156±4008 0.1868 0.3504 0.1964 
Acinetobacter 
calcoaceticus Nosocomial infection Gc00201 3598 3325 21074±4645 20626±4573 21373±4622 0.2036 0.3657 0.2168 
Actinobacillus 
pleuropneumoniae 
Necrotizing 
pleuropneumonia Gc00708 2242 2036 13015±2854 12798±2808 13221±2833 0.2565 0.3499 0.2346 
Aeromonas 
hydrophila 
hydrophila 
Gastroenteritis, 
Septicemia, Food 
poisoning 
Gc00456 4744 4122 24703±5644 24118±5315 25373±5553 0.1843 0.2633 0.1312 
Aeromonas 
salmonicida 
salmonicida 
Furunculosis Gc00536 4702 4086 23482±5284 22944±4991 24103±5246 0.1890 0.2653 0.1355 
Anaplasma 
marginale Anaplasmosis Gc00239 1197 949 6919±1536 6723±1466 7152±1639 0.1350 0.2108 0.0867 
Anaplasma 
phagocytophilum Anaplasmosis Gc00351 1471 1264 7080±1571 6916±1544 7282±1617 0.1842 0.2470 0.1301 
Arcobacter 
butzleri 
Bacteremia, 
Gastroenteritis Gc00657 2341 2259 16597±3902 16502±4006 16797±3699 0.4185 0.3915 0.3591 
Bacillus anthracis Anthrax Gc00189 5227 5309 31589±7108 31303±7157 31971±6753 0.3655 0.3868 0.3245 
Bacillus cereus Food poisoning Gc00173 5224 5603 33351±7428 33086±7480 33715±7080 0.3804 0.3964 0.3410 
Bacillus 
licheniformis Food poisoning Gc00213 4222 4152 23972±5311 23715±5265 24447±5125 0.3388 0.3165 0.2507 
Bacteroides 
fragilis Diarrhea, Abscesses Gc00260 5205 4184 30522±6601 30276±6557 31142±6555 0.3746 0.3083 0.2628 
Bacteroides 
thetaiotaomicron Peritonitis Gc00126 6260 4778 35884±7660 35563±7597 36516±7751 0.3674 0.3154 0.2658 
Bacteroides 
vulgatus 
Opportunistic 
peritoneal disease Gc00584 5163 4065 28893±6119 28651±6052 29445±6250 0.3597 0.3302 0.2742 
Bartonella 
henselae 
Bacillary 
angiomatosis Gc00192 1931 1488 9206±1997 9048±1958 9427±2013 0.2483 0.2778 0.1780 
Bartonella 
quintana 
Bacillary 
angiomatosis, 
Endocarditis, Trench 
fever 
Gc00191 1581 1142 7710±1699 7544±1666 7896±1705 0.1998 0.2801 0.1564 
Bdellovibrio 
bacteriovorus Cell lysis Gc00168 3782 3587 21121±4611 20600±4493 21603±4929 0.1654 0.2899 0.1478 
Bordetella 
parapertussis Respiratory infection Gc00147 4773 4185 22589±5550 21833±5067 23661±5670 0.1177 0.1520 0.0469 
Bordetella 
pertussis Respiratory infection Gc00146 4086 3436 18390±4527 17731±4121 19260±4681 0.1024 0.1534 0.0432 
Borrelia afzelii 
Lyme disease, 
Acrodermatitis 
chronica atrophicans 
Gc00408 905 856 7545±1708 7616±1778 7590±1624 0.3624 0.4436 0.4718 
Borrelia 
burgdorferi Lyme disease Gc00012 910 851 7635±1733 7699±1803 7690±1652 0.3767 0.4331 0.4896 
Borrelia garinii Lyme disease Gc00211 904 832 7395±1673 7446±1734 7447±1603 0.3963 0.4338 0.4996 
Borrelia hermsii Tick-borne relapsing fever Gc00792 922 819 7605±1724 7668±1791 7695±1634 0.3786 0.3905 0.4707 
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Borrelia turicatae Tick-borne relapsing fever Gc00791 9173 818 7763±1784 7828±1859 7860±1684 0.3778 0.3851 0.4663 
Brucella abortus Brucellosis Gc00263 3287 3085 15773±3805 15314±3590 16508±3809 0.1484 0.1516 0.0584 
Brucella 
melitensis Brucellosis Gc00074 3294 3198 16505±3949 16052±3726 17265±3953 0.1605 0.1524 0.0623 
Brucella suis Brucellosis, Fever, Infectious abortions Gc00699 3323 3241 16270±3886 15819±3661 17000±3886 0.1574 0.1585 0.0641 
Burkholderia 
cenocepacia 
Chronic infection, 
Necrotizing 
Pneumonia 
Gc00744 7900 7008 34542±8237 33395±7622 36080±8521 0.1131 0.1604 0.0508 
Burkholderia 
mallei Glanders, Pneumonia Gc00518 5900 5852 24519±5794 23776±5247 25689±6100 0.1316 0.1420 0.0471 
Burkholderia 
multivorans Cepacia syndrome Gc00689 6820 6121 32560±7692 31521±7102 33960±8004 0.1202 0.1668 0.0557 
Burkholderia 
pseudomallei 
Pneumonia, 
Bacteremia, 
Melioidosis 
Gc00520 7100 7183 32157±7571 31144±6874 33613±7981 0.1216 0.1537 0.0495 
Burkholderia 
vietnamiensis Pneumonia Gc00531 7430 7617 33383±7916 32235±7273 34852±8335 0.1036 0.1624 0.0486 
Burkholderia 
xenovorans 
(fungorum) 
Opportunistic 
infection Gc00365 9279 8702 46606±10914 45002±10138 48476±11425 0.1010 0.1815 0.0561 
Campylobacter 
concisus 
Gingivitis, 
Periodontitis, 
Periodontosis, 
Gastroenteritis 
Gc00644 2052 1929 11849±2753 11758±2783 12204±2635 0.3881 0.2453 0.2174 
Campylobacter 
curvus 
Gastroenteritis, 
Periodontal infection Gc00628 1971 1931 12086±2771 11987±2783 12425±2642 0.3799 0.2564 0.2219 
Campylobacter 
fetus fetus 
Bacteremia, 
Infertility, 
Septicemia, 
Meningitis 
Gc00466 1773 1719 11959±2849 11858±2909 12283±2689 0.3809 0.2716 0.2374 
Campylobacter 
jejuni jejuni 
Diarrhea, 
Gastroenteritis, Food 
poisoning 
Gc00491 1616 1653 11426±2562 11457±2621 11577±2383 0.4583 0.3761 0.4113 
Campylobacter 
lari 
Bacteremia, 
Diarrhea, Food 
poisoning, 
Gastroenteritis 
Gc00851 1562 1599 10676±2320 10703±2362 10803±2214 0.4603 0.3854 0.4187 
Candidatus 
Protochlamydia 
amoebophila 
Pneumonia Gc00185 2414 2031 13565±2812 13476±2807 13470±2836 0.3928 0.4286 0.4961 
Chlamydia 
muridarum 
Pharyngitis, 
Bronchitis, 
Pneumonia, 
Respiratory infection 
Gc00028 1072 904 6170±1313 6049±1293 6241±1360 0.2159 0.3859 0.2407 
Chlamydia 
trachomatis 
Bronchitis, Heart 
disease, Pharyngitis, 
Pneumonia, 
Respiratory 
infection, Trachoma, 
Venereal disease 
Gc00017 1042 895 6007±1291 5883±1267 6084±1331 0.2044 0.3743 0.2248 
Chlamydophila 
abortus 
Pharyngitis, 
Bronchitis, 
Pneumonia, 
Respiratory infection 
Gc00262 1144 932 6630±1421 6521±1416 6687±1430 0.2550 0.4157 0.2869 
Chlamydophila 
pneumoniae 
Pharyngitis, 
Bronchitis, 
Pneumonia, Heart 
disease, Respiratory 
infection 
Gc00143 1225 1113 7387±1560 7268±1543 7438±1582 0.2572 0.4305 0.2995 
Chromobacterium 
violaceum Diarrhea, Septicemia Gc00157 4751 4407 22494±5283 21847±4846 23367±5441 0.1431 0.1898 0.0725 
Citrobacter koseri 
Bacteremia, Brain 
abscesses, 
Meningoencephalitis, 
Neonatal meningitis 
Gc00642 4720 5003 28306±6188 27612±5922 28928±6208 0.1664 0.2961 0.1460 
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Clostridium 
botulinum Botulism Gc00741 3992 3655 23971±5592 23730±5681 24467±5397 0.3563 0.3178 0.2639 
Clostridium 
difficile 
Diarrhea, Colitis, 
Peritonitis Gc00420 4290 3742 26564±6412 26124±6506 27255±6245 0.2791 0.2826 0.1996 
Clostridium 
perfringens 
Dysenteria, 
Enterocolitis, 
Enterotoxemia, Food 
poisoning, Gas 
gangrene 
Gc00406 3256 2876 18878±4506 18730±4584 19400±4242 0.3898 0.2672 0.2370 
Clostridium tetani Tetanus Gc00120 2799 2373 18240±4199 18081±4260 18631±4105 0.3730 0.3096 0.2656 
Corynebacterium 
diphtheriae gravis 
Diphtheria, 
Respiratory infection Gc00163 2488 2272 12322±3052 11767±2926 12830±3196 0.0584 0.1882 0.0447 
Corynebacterium 
jeikeium 
Endocarditis, 
Septicemia, 
Meningitis, 
Nosocomial infection 
Gc00271 2462 2104 11183±2838 10672±2686 11739±3007 0.0595 0.1494 0.0327 
Corynebacterium 
urealyticum 
Cystitis, Pyelitis, 
Urinary tract 
infection 
Gc00755 2369 2024 10616±2640 10185±2486 11118±2738 0.0790 0.1560 0.0401 
Coxiella burnetii Food poisoning Gc00692 2016 1930 12824±2643 12776±2602 12901±2601 0.4375 0.4386 0.4086 
Ehrlichia 
chaffeensis 
Ehrlichiosis, Human 
monocytic 
ehrlichiosis 
Gc00353 1176 1105 7907±1729 7804±1763 7993±1720 0.3058 0.3958 0.3023 
Enterobacter 
sakazakii 
Meningitis, 
Septicemia, 
Necrotizing 
enterocolitis 
Gc00638 4368 4277 24007±5218 23480±4948 24594±5261 0.1912 0.2746 0.1438 
Enterococcus 
faecalis 
Bacteremia, 
Endocarditis, 
Urinary infection 
Gc00831 2739 2701 18533±4090 18323±4088 18760±3981 0.3306 0.3833 0.3026 
Escherichia coli Diarrhea Gc00716 4686 4126 29392±6442 28654±6199 30050±6555 0.1618 0.2931 0.1433 
Francisella 
philomiragia 
Bacteremia, 
Pneumonia, 
Septicemia 
Gc00722 2045 1911 14775±3443 14622±3505 14931±3225 0.3523 0.4040 0.3326 
Francisella 
tularensis Tularemia Gc00241 1892 1603 11937±2715 11810±2749 12039±2605 0.3443 0.4206 0.3424 
Fusobacterium 
nucleatum 
nucleatum 
Periodontal infection Gc00085 2170 2067 14465±3377 14476±3456 14784±3182 0.4891 0.3064 0.3309 
Granulibacter 
bethesdensis 
Chronic 
granulomatous Gc00423 2708 2437 13697±3305 13213±3077 14332±3446 0.1017 0.1540 0.0457 
Haemophilus 
ducreyi 
Genital ulcer, 
Chancroid Gc00142 1698 1717 9470±2049 9291±2014 9569±2051 0.2260 0.3986 0.2543 
Haemophilus 
influenzae 
Otitis, Meningitis, 
Septicemia, 
Sinusitis, Bronchitis 
Gc00001 1830 1657 10640±2330 10462±2291 10852±2324 0.2560 0.3138 0.2077 
Haemophilus 
somnus 
Arthritis, 
Myocarditis, 
Pneumonia 
Gc00743 2263 1980 11524±2533 11307±2499 11710±2538 0.2313 0.3476 0.2201 
Helicobacter 
pylori 
Gastric 
inflammation, Ulcer Gc00879 1673 1567 10030±2103 9998±2111 10098±2064 0.4475 0.4316 0.4091 
Klebsiella 
pneumoniae 
Bacteremia, 
Pneumonia, Urinary 
tract infection 
Gc00841 5641 5425 29171±6561 28491±6262 29909±6474 0.1855 0.2740 0.1406 
Legionella 
pneumophila Legionellosis Gc00226 3345 2878 21074±4478 20803±4455 21141±4445 0.3014 0.4681 0.3571 
Leptospira 
borgpetersenii 
hardjobovis 
Leptospirosis Gc00433 3920 2945 19500±4144 19288±4116 19667±4101 0.3306 0.4150 0.3290 
Listeria 
monocytogenes 
Food poisoning, 
Listeriosis Gc00186 2905 2821 17937±4140 17600±4133 18305±3994 0.2431 0.3173 0.2044 
Mycobacterium 
abscessus 
Broncho-pulmonary 
infection, 
Respiratory 
infection, Wound 
infection 
Gc00729 5067 4920 24543±6186 23410±5792 25751±6546 0.0562 0.1502 0.0309 
 72
Mycobacterium 
avium 
Respiratory 
infection, 
Tuberculosis type 
pulmonary infection 
Gc00462 5475 5120 23353±6182 22194±5736 24817±6661 0.0519 0.1049 0.0182 
Mycobacterium 
avium 
paratuberculosis 
Johne's disease, 
Paratuberculosis, 
Enteritis 
Gc00169 4829 4350 21675±5713 20621±5284 23029±6117 0.0545 0.1047 0.0184 
Mycobacterium 
bovis Tuberculosis Gc00138 4345 3920 19755±5050 18796±4688 20854±5432 0.0497 0.1247 0.0221 
Mycobacterium 
bovis BCG Bovine tuberculosis Gc00489 4374 3952 19934±5100 18969±4732 21050±5486 0.0503 0.1234 0.0220 
Mycobacterium 
leprae 
Leprosy, Hanson's 
disease Gc00045 3268 1605 9120±2335 8658±2202 9609±2524 0.0434 0.1341 0.0235 
Mycobacterium 
marinum Tuberculosis Gc00784 6636 5423 28943±7417 27506±6949 30423±7938 0.0466 0.1452 0.0266 
Mycobacterium 
smegmatis Soft tissue lesions Gc00461 6988 6716 32660±8582 31102±8048 34619±9073 0.0579 0.1131 0.0217 
Mycobacterium 
tuberculosis Tuberculosis Gc00578 4424 3950 20040±5081 19073±4713 21124±5483 0.0492 0.1294 0.0232 
Mycobacterium 
ulcerans Buruli ulcer Gc00469 5631 4160 20218±5218 19169±4838 21314±5711 0.0405 0.1334 0.0217 
Mycoplasma 
arthritidis Arthritis Gc00825 820 631 4728±998 4682±1013 4715±1041 0.3462 0.4724 0.4377 
Mycoplasma 
genitalium 
Urogenital infection, 
Respiratory 
infection, Non-
gonococcal urethritis 
Gc00002 580 477 4034±836 4017±849 4015±860 0.4314 0.4542 0.4974 
Mycoplasma 
penetrans 
Urogenital infection, 
Respiratory infection Gc00110 1358 1037 8755±1969 8662±1991 8690±1990 0.3445 0.4304 0.4736 
Mycoplasma 
pneumoniae 
Pneumonia, 
Tracheobronchitis, 
Respiratory infection 
Gc00005 816 689 6227±1330 6293±1364 6172±1331 0.3367 0.4118 0.3333 
Neisseria 
gonorrhoeae Gonorrhea Gc00258 2153 2002 10711±2295 10488±2158 10987±2423 0.2008 0.2617 0.1413 
Neisseria 
meningitidis 
Meningitis, 
Septicemia Gc00026 2272 2063 10104±2187 9898±2081 10378±2282 0.2079 0.2529 0.1401 
Neorickettsia 
sennetsu Sennetsu fever Gc00352 859 932 5766±1265 5712±1268 5895±1223 0.3561 0.2934 0.2419 
Nocardia farcinica Nocardiosis, Mastitis Gc00224 6021 5683 26116±6921 24917±6314 27781±7320 0.0656 0.1010 0.0189 
Parabacteroides 
distasonis 
Opportunistic 
peritoneal disease Gc00583 4811 3850 28852±6264 28651±6238 29468±6162 0.3916 0.2999 0.2639 
Pasteurella 
multocida 
Pasteurellosis, 
Cholera, Septicemia Gc00048 2257 2015 13526±2959 13315±2905 13708±2895 0.2700 0.3716 0.2578 
Porphyromonas 
gingivalis 
Dental plaque, 
Periodontal infection Gc00809 2354 2090 13339±2871 13275±2830 13739±2836 0.4251 0.2282 0.2155 
Propionibacterium 
acnes 
Acne Gc00204 2560 2297 12996±3347 12326±3179 13641±3565 0.0418 0.1536 0.0277 
Proteus mirabilis 
Encephalitis, 
Pneumonia, 
Pyelonephritis, 
Septicemia, Surgical 
wound infection, 
Ulcer, Urinary tract 
infection, 
Urolithiasis 
Gc00758 4063 3693 22802±5068 22364±4999 23152±4996 0.2293 0.3560 0.2243 
Pseudomonas 
aeruginosa 
Opportunistic 
infection, 
Nocosomial infection 
Gc00432 6537 5892 32928±7633 32280±7041 34239±7495 0.2301 0.1797 0.0946 
Pseudomonas 
mendocina 
Endocarditis, 
Spondylodiscitis Gc00544 5072 4594 25846±6022 25287±5593 26784±5865 0.2099 0.2026 0.1022 
Rickettsia bellii Epidemic typhus Gc00661 1528 1476 9556±2129 9492±2186 9582±2043 0.3992 0.4735 0.4200 
Rickettsia 
canadensis Epidemic typhus Gc00660 1159 1093 7112±1594 7078±1638 7144±1513 0.4272 0.4576 0.4217 
Rickettsia conorii Rocky Mountain Spotted Fever Gc00062 1268 1374 8045±1775 7988±1816 8088±1709 0.3922 0.4489 0.3944 
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Rickettsia 
prowazekii 
Typhus, Rocky 
Mountain Spotted 
Fever 
Gc00018 1111 835 7260±1621 7249±1677 7277±1536 0.4777 0.4784 0.4684 
Rickettsia 
rickettsii 
Rocky Mountain 
Spotted Fever Gc00736 1257 1345 7436±1648 7374±1687 7479±1583 0.3747 0.4447 0.3810 
Rickettsia typhi Typhus Gc00208 1111 838 7186±1602 7164±1653 7212±1528 0.4544 0.4645 0.4432 
Salmonella 
enterica enterica 
Food poisoning, 
Gastroenteritis, 
Salmonellosis 
Gc00833 4685 4318 25874±5635 25253±5414 26418±5671 0.1723 0.2980 0.1502 
Salmonella 
enterica sv 
Paratyphi A 
Food poisoning, 
Gastroenteritis, 
Salmonellosis, 
Typhoid fever 
Gc00853 4581 4078 24585±5427 23997±5208 25131±5404 0.1708 0.3036 0.1537 
Salmonella 
enterica sv 
Paratyphi A 
Food poisoning, 
Gastroenteritis, 
Salmonellosis, 
Typhoid fever 
Gc00238 4585 4093 28451±6197 27834±5959 29034±6155 0.1746 0.2958 0.1501 
Salmonella 
enterica sv Typhi 
Typhoid fever, 
Salmonellosis, Food 
poisoning 
Gc00066 4809 4395 25456±5596 24843±5356 26012±5603 0.1951 0.3081 0.1688 
Serratia 
proteamaculans Pneumonia Gc00647 5448 4891 30454±6854 29710±6536 31154±6733 0.1740 0.2929 0.1462 
Shigella boydii Dysenteria, Food poisoning Gc00779 4615 4246 22229±4780 21699±4539 22648±4871 0.1686 0.3205 0.1621 
Shigella 
dysenteriae 
Dysenteria, Food 
poisoning Gc00324 4369 4274 21088±4422 20522±4135 21444±4595 0.1331 0.3344 0.1488 
Shigella flexneri 
Dysenteria, 
Gastroenteritis, Food 
poisoning 
Gc00130 4599 4068 23543±5078 22989±4839 24010±5130 0.1729 0.3121 0.1592 
Shigella sonnei Dysenteria, Food poisoning Gc00323 5039 4461 24441±5249 23862±4983 24912±5377 0.1703 0.3163 0.1606 
Staphylococcus 
aureus 
Mastitis, Nosocomial 
infection Gc00327 2515 2665 18106±4153 17948±4241 18367±3890 0.3727 0.3684 0.3140 
Staphylococcus 
haemolyticus 
Opportunistic 
infection Gc00274 2685 2676 17340±3945 17207±4023 17582±3713 0.3869 0.3711 0.3238 
Streptococcus 
agalactiae Meningitis Gc00100 2211 2094 12858±2930 12638±2948 13092±2877 0.2601 0.3353 0.2285 
Streptococcus 
gordonii 
Dental plaque, 
Endocarditis, 
Periodontal infection 
Gc00643 2196 2051 13014±2945 12895±2958 13286±2829 0.3647 0.3106 0.2602 
Streptococcus 
mutans Dental caries Gc00109 2030 1960 12205±2735 12118±2770 12415±2651 0.3939 0.3406 0.3015 
Streptococcus 
pneumoniae 
Meningitis, 
Pneumonia, Otitis 
media 
Gc00437 2000 1914 12092±2702 11967±2722 12331±2619 0.3458 0.3182 0.2580 
Streptococcus 
pyogenes 
Bone infection, 
Endocarditis, 
Mastoiditis, 
Meningitis, Myositis, 
Necrotizing fasciitis, 
Otitis, Pharyngitis, 
Pneumonia, 
Sinusitis, Tonsillitis 
Gc00285 1838 1865 10563±2399 10376±2396 10801±2403 0.2530 0.2985 0.1976 
Streptococcus suis 
Meningitis, 
Endocarditis, 
Septicemia, Arthritis 
Gc00546 2096 2186 12022±2696 11867±2694 12293±2660 0.3108 0.2955 0.2225 
Treponema 
pallidum pallidum Syphilis Gc00789 1139 1028 6849±1410 6676±1310 7002±1533 0.1435 0.2829 0.1264 
Tropheryma 
whipplei Whipple's disease Gc00123 925 783 5486±1270 5331±1245 5654±1276 0.1467 0.2404 0.1079 
Ureaplasma 
parvum 
Respiratory 
infection, Urinary 
tract infection 
Gc00742 751 609 5510±1196 5469±1221 5498±1212 0.3847 0.4797 0.4533 
Vibrio cholerae Cholera, Food poisoning Gc00557 4148 3875 22495±4906 21872±4736 22891±5091 0.1368 0.3337 0.1552 
Vibrio 
parahaemolyticus Gastroenteritis Gc00124 5165 4832 27525±6192 26701±6047 28124±6419 0.1263 0.3035 0.1330 
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Yersinia 
enterocolitica 
Gastroenteritis, Food 
poisoning Gc00481 4615 3979 25630±5744 24958±5547 26182±5722 0.1696 0.2958 0.1485 
Yersinia pestis Bubonic and Pneumonic plague Gc00538 4517 3850 23982±5310 23393±5121 24516±5316 0.1566 0.3041 0.1466 
Yersinia 
pseudotuberculosis Gastroenteritis Gc00776 4695 4150 25461±5702 24847±5530 26020±5664 0.1766 0.3005 0.1556 
 
 
 
 
 
1. Non redundant, complete bacterial genomes classified as “relevant human pathogens” in the 
Genome OnLine Database v2.0 (GOLD database update October 30th 2008, 
http://www.genomesonline.org/) under analysis 
2. Genome size in Kilobases 
3. Number of Open Reading Frame in the genome 
5. Mean Number of potential epitopes of the genome under analysis, equivalent to the affinity of 
1% of the best binder peptides, recognized by the different study populations 
5. p value for the comparison between groups indicated. Students' t-test. Statistically significant 
comparisons (p<0.05) are indicated in bold. 
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Table 3. HLA-DRB1 allelic frequency analysis of the study population. 
 
 Controls 
Chronic 
Sarcoidosis Loefgren  
CTR  
vs  
Chr Sarc 
CTR  
vs  
Loef 
Chr Sarc 
vs  
Loef 
HLA-DRB1 
Allele N Freq N Freq N Freq  χ-square p χ-square p χ-square p 
0101 57 0.064 12 0.055 6 0.077  0.7250 0.8312 0.6627 
0102 4 0.004 0 0.000 0 0.000  0.7152 0.7413 NA 
0103 3 0.003 0 0.000 0 0.000  0.8932 0.5811 NA 
0301 103 0.115 21 0.095 16 0.205  0.4746 0.0321* 0.0201* 
0302 2 0.002 0 0.000 0 0.000  0.8519 0.3764 NA 
0401 57 0.064 13 0.059 3 0.038  0.9199 0.5189 0.6876 
0402 6 0.007 1 0.005 0 0.000  0.9108 0.9777 0.5872 
0403 10 0.011 0 0.000 1 0.013  0.2393 0.6693 0.5872 
0404 41 0.046 4 0.018 2 0.026  0.0936 0.5852 0.9473 
0405 9 0.010 1 0.005 0 0.000  0.7048 0.7841 0.5872 
0406 1 0.001 0 0.000 0 0.000  0.4471 0.1221 NA 
0407 9 0.010 1 0.005 4 0.051  0.7048 0.0116* 0.0246* 
0408 8 0.009 0 0.000 0 0.000  0.3358 0.8528 NA 
0701 74 0.083 15 0.068 6 0.077  0.5644 0.9725 0.9986 
0801 18 0.020 8 0.036 1 0.013  0.2384 0.9832 0.5100 
0803 6 0.007 1 0.005 0 0.000  0.9108 0.9777 0.5872 
0804 2 0.002 2 0.009 0 0.000  0.3716 0.3764 0.9698 
0812 1 0.001 0 0.000 0 0.000  0.4471 0.1221 NA 
0901 10 0.011 4 0.018 1 0.013  0.6194 0.6693 0.8444 
1001 6 0.007 3 0.014 1 0.013  0.5435 0.9313 0.6039 
1101 78 0.087 29 0.132 4 0.051  0.0598 0.3769 0.0823 
1102 5 0.006 0 0.000 1 0.013  0.5831 0.9777 0.5872 
1103 7 0.008 2 0.009 0 0.000  0.8156 0.9313 0.9698 
1104 51 0.057 5 0.023 2 0.026  0.0555 0.3620 0.7725 
1201 10 0.011 2 0.009 0 0.000  0.9244 0.7234 0.9698 
1202 4 0.004 1 0.005 0 0.000  0.5831 0.7413 0.5872 
1301 94 0.105 16 0.073 9 0.115  0.1876 0.9283 0.3524 
1302 52 0.058 18 0.082 3 0.038  0.2543 0.6406 0.3039 
1303 13 0.015 0 0.000 1 0.013  0.1474 0.7091 0.5872 
1305 1 0.001 1 0.005 0 0.000  0.8519 0.1221 0.5872 
1326 1 0.001 0 0.000 0 0.000  0.4471 0.1221 NA 
1401 33 0.037 13 0.059 3 0.038  0.1964 0.8079 0.6876 
1404 1 0.001 0 0.000 0 0.000  0.4471 0.1221 NA 
1407 2 0.002 0 0.000 0 0.000  0.8519 0.3764 NA 
1501 86 0.096 44 0.200 13 0.167  0.00002^ 0.0754 0.6344 
1502 9 0.010 0 0.000 0 0.000  0.2829 0.7841 NA 
1601 19 0.021 2 0.009 1 0.013  0.3620 0.9305 0.7065 
1602 1 0.001 1 0.005 0 0.000  0.8519 0.1221 0.5872 
*Bonferroni corrected p>0.05 
^Bonferroni corrected p=0.0013 
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Table 5. Analysis of the HLA-DRB1 alle frequency in the study population subgroups ranked 
by the percentile recognition of M. avium immunome. 
 
A. 76°-100° percentile of M. avium immunome 
 Loefgren 
Chronic 
Sarcoidosis Controls  
CTR  
vs  
Chr Sarc 
CTR  
vs  
Loef 
Chr Sarc 
vs  
Loef 
HLA-DRB1 
Allele N Freq N Freq N Freq  χ-square p χ-square p χ-square p 
0101 4 0,142857 2 0,0625 12 0,065934  0,752637 0,29569 0,545972 
0102 0 0 0 0 3 0,016484  0,933209 0,86417 NA 
0301 11 0,392857 12 0,375 71 0,39011  0,972137 0,856908 0,901165 
0401 1 0,035714 1 0,03125 5 0,027473  0,644641 0,714702 0,532173 
0404 2 0,071429 1 0,03125 6 0,032967  0,62522 0,645852 0,905486 
0405 0 0 0 0 1 0,005495  0,324589 0,279601 NA 
0408 0 0 0 0 2 0,010989  0,688938 0,625769 NA 
0701 1 0,035714 3 0,09375 14 0,076923  0,976218 0,693497 0,703662 
0801 1 0,035714 0 0 4 0,021978  0,889536 0,824374 0,94628 
1101 2 0,071429 2 0,0625 11 0,06044  0,721656 0,844175 0,703662 
1102 1 0,035714 0 0 0 0  NA 0,279601 0,94628 
1104 1 0,035714 0 0 10 0,054945  0,366004 0,975771 0,94628 
1301 3 0,107143 0 0 17 0,093407  0,147756 0,908241 0,191528 
1305 0 0 0 0 1 0,005495  0,324589 0,279601 NA 
1401 1 0,035714 4 0,125 12 0,065934  0,419583 0,844175 0,435253 
1501 0 0 7 0,21875 13 0,071429  0,020827 0,298833 0,025735 
 
B. 26°-50° percentile of M. avium immunome 
 Loefgren 
Chronic 
Sarcoidosis Controls  
CTR  
vs  
Chr Sarc 
CTR  
vs  
Loef 
Chr Sarc 
vs  
Loef 
HLA-DRB1 
Allele N Freq N Freq N Freq  χ-square p χ-square p χ-square p 
0401 1 0,1 6 0,083333 31 0,186747  0,067584 0,788224 0,669285 
0402 0 0 1 0,013889 2 0,012048  0,60619 0,235259 0,245069 
0404 0 0 1 0,013889 11 0,066265  0,169496 0,866468 0,245069 
0405 0 0 1 0,013889 3 0,018072  0,750289 0,407113 0,245069 
0408 0 0 0 0 3 0,018072  0,60619 0,407113 NA 
0701 0 0 3 0,041667 18 0,108434  0,155789 0,574302 0,809451 
0801 0 0 6 0,083333 6 0,036145  0,227886 0,775284 0,763971 
0804 0 0 0 0 1 0,006024  0,666602 0,054871 NA 
1101 2 0,2 13 0,180556 22 0,13253  0,446225 0,897053 0,773789 
1102 0 0 0 0 3 0,018072  0,60619 0,407113 NA! 
1104 0 0 1 0,013889 3 0,018072  0,750289 0,407113 0,245069 
1301 3 0,3 11 0,152778 18 0,108434  0,456291 0,189295 0,477119 
1302 0 0 6 0,083333 15 0,090361  0,941676 0,681216 0,763971 
1501 4 0,4 23 0,319444 28 0,168675  0,01502 0,155656 0,881651 
1502 0 0 0 0 2 0,012048  0,871005 0,235259 NA 
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Table 6. Comparison of the recognition of the HLA-DR immunomes of M. avium and M. 
tuberculosis in the study populations in comparison to tuberculosis patients. 
 
 
Genome 
Mean Number of potential epitopes (1% affinity)1 
  
Student's t-test (p-value)2 
Controls Chronic Sarcoidosis Loefgren Tuberculosis
3 
TB 
vs  
Control 
TB  
vs  
Loefgren 
TB 
vs  
Chronic 
Sarcoidosis 
M. avium 23353±6182 22194±5736 24817±6661 20709±6894 0.0002 >0.00001 0.003 
M. 
tuberculosis 20040±5081 19073±4713 21124±5483 17925±5732 0.0008 >0.00001 0.01 
 
 
 
1. Mean Number of potential epitopes in the different study population of the M. avium and M. 
tuberculosis, equivalent or higher than the affinity of 1% of the best binder peptides for the subject's 
HLA-DR molecules 
2. p value for the comparison between groups indicated.  Students' t-test. Statistically significant 
comparisons (p<0.05) are indicated in bold 
3. Matched controls of the tuberculosis patient populations did not differ from the control 
population of this study in terms of the number of potential epitopes recognized (M. avium: 
23353±6182 vs 22591±7612; M. tuberculosis: 20040±5081 vs 19472±4972; p>0.05 all 
comparisons). 
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